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Abstract 
During the course of HIV-1 disease, virus neuroinvasion occurs as an early 
event, within weeks following infection. Intriguingly, subsequent central nervous system 
(CNS) complications manifest only decades after the initial virus exposure. In the 
current era of combined anti-retroviral therapy (cART), while the virus replication in the 
periphery is brought under complete control, in the CNS owing to poor drug penetrance, 
there occurs development of increasing neurocognitive complications. So while the HIV-
infected patients are living longer and have decreased incidence of the disease, the 
prevalence of HIV-associated neurocognitive disorders (HAND) is actually on a rise. 
Although CNS is commonly regarded as an immune-privileged site, emerging evidence 
indicates that innate immunity elicited by the CNS glial cells is a critical determinant for 
the establishment of protective immunity. Sustained expression of the protective 
immune responses manifested as increased expression of a mediator, such as platelet-
derived growth factor (PDGF), however, can be a double-edged sword. While PDGF 
has been defined as a neuroprotective immune mediator, in concert with other 
inflammatory mediators (elicited by HIV or its protein products), it can tip the balance 
from a protective to a toxic state in the CNS. Herein, we present an overview of some of 
the essential elements of the cerebral innate immunity in HIV neuropathogenesis 
including the role that platelet-derived growth factor (PDGF) released from astrocytes 
has in exacerbating HAND.  
Out of the various PDGF isoforms, PDGF-BB is critical for astrocytes and hence 
is the focus of our study. PDGF-BB exposure to astrocytes results in astrogliosis and 
release of the chemokine monocyte chemotactic protein-1 (MCP-1), the two hallmark 
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features of HAND.  To further understand these observations and explore the role of 
PDGF-BB regulation in HAND, our central hypothesis is that exposure of astrocytes to 
HIV transactivating protein Tat results in the release of growth factors such as PDGF-
BB, which could ultimately lead to enhanced astrogliosis and blood-brain barrier(BBB) 
disruption. The aim of this study was to explore the mechanism of PDGF-BB regulation 
in astrocytes as it relates to HAND pathogenesis. 
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Introduction/Overview 
 Almost 60 million people have been infected worldwide with HIV-1 since its 
discovery.  This global epidemic leaves 25 million HIV-related deaths in its wake with 
approximately 33 million people still infected [1]. Combined anti-retroviral therapy 
(cART) is able to control HIV replication in the periphery, significantly extending the 
longevity of those infected with HIV-1 [2, 3]. However, while cART is able to control the 
virus in the periphery, the drugs have inferior penetration across the blood-brain barrier 
(BBB) [4]. Hence although HIV-1 infected patients enjoy the benefits of longevity, they 
now have to deal with the long-term central nervous system (CNS) complications 
associated with HIV-1 infection, termed collectively as HIV-associated neurocognitive 
disorders (HAND). Additionally, it is also becoming evident that most age-related 
complications are also an integral part of individuals on cART.    
 During the course of HIV-1 disease, viral  neuroinvasion occurs within weeks of 
infection [5, 6] via the “Trojan Horse” theory [7]. HIV does not enter the brain directly; 
rather it gains access into the brain by infecting monocytes in the periphery.  These 
infected monocytes can now pass through BBB into the brain.  Intriguingly, subsequent 
CNS complications manifest decades after the initial infection.  Although the CNS was 
once regarded as an immune-privilege site, emerging evidence suggests that innate 
immune responses elicited by glial cells are critical for the establishment of protective 
immunity.  Studies have revealed that the severity of HIV-associated dementia 
(HAD)/HIV-encephalitis (HIVE), the two extreme forms of HAND, correlates with 
the presence of activated glial cells rather than with the presence and amount of 
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HIV-infected cells or virus replication in the CNS [2, 8, 9]. These immune responses 
by activated glia include release of protective mediators including growth factors, 
chemokines and cytokines, which while protective for neurons, may actually have 
deleterious effects on other types of cells in the CNS. Below is a stepwise introduction 
of HAND and the various mediators that have been used in our study. 
HIV and HIV-associated Neurocognitive Disorders (HAND) 
 The Human Immunodeficiency Virus (HIV), a member of the lentivirus family, that  
causes acquired immunodeficiency syndrome (AIDS) was discovered during the 1980s 
in humans but was thought to have originated from the non-human primates in Sub-
Sahara Africa [10-12].  The virus is transmitted sexually, through intravenous (IV) drug 
use or maternally from mother to child. Once a person becomes infected, the HIV 
targets T lymphocytes and monocytes by binding to the CD4+ receptors on the surface 
gaining entry into these cells.  Here, the virus hijacks the host cellular machinery 
ultimately killing the cell and reducing the overall CD4+ T cell population critical in 
immune defense. The immune system becomes severely suppressed making the 
individual susceptible to a variety of opportunistic infections, to which they eventually 
succumb. Due to the pandemic effect that this disease has had worldwide, much 
scientific research has been undertaken to better understand the pathogenesis of HIV-
1.  These studies have led to exciting breakthroughs which, in concert have paved the 
way for discovery of effective anti-retroviral therapeutic drugs including non-nucleoside 
reverse inhibitors (NNRTIs), nucleoside reverse inhibitors (NRTIs), protease and fusion 
inhibitors [12, 13].  The advances of cART successfully control viral replication in the 
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periphery significantly extending the lifespan of those infected with HIV-1. However, 
despite its efficacy in peripheral viral suppression, these drugs have limited BBB 
penetration in the brain [4] consequently, the brain now becomes a reservoir for the 
virus. It has been shown that the virus enters the brain shortly after infection [6], and 
owing to the limited penetrance of cART in the CNS, the virus can infect microglia and 
to a lesser, extent astrocytes in this milieu.  Infected microglia and astroglia can then 
become activated producing a plethora of cytokines/chemokines, viral proteins as well 
as other toxic mediators resulting in the dysfunction/death of surrounding neurons and 
the development of HAND.  Various neurocognitive conditions ranging from 
Asymptomatic Neurocognitive Impairment (ANI), Minor Cognitive Motor Disorders 
(MCMD), and HIV-associated dementia (HAD) in the most severe form are included 
under the umbrella of HAND. It is intriguing that almost 60% of HIV-infected individuals 
will develop HAND in their lifetime, affecting their daily functioning and thus quality of life 
[3, 14]. These patients are diagnosed by changes in behavioral, cognitive and motor 
abnormalities [14]. HAD, the most severe form of HIV- induced CNS impairment is 
clinically characterized by motor and behavioral dysfunctions that, in the absence of 
therapy could lead to seizures, coma and death within six months of onset [9]. 
Pathological correlates of HAD include astrogliosis, microglial activation, monocyte 
infiltration and neuronal damage. With the increasing prevalence of HAND which affects 
the normal functioning of the affected individuals and their quality of life, it is very 
important to understand the cellular and molecular mechanisms by which HIV-1 
infection exerts its detrimental effects in the progression of HAND.  
Critical Role of Astrocytes in HAND 
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Astrocytes, the most abundant cells of the CNS once believed to be involved 
primarily in providing and maintaining structural support, are now recognized not only as 
critical players in the overall health of the CNS, but also as a key mediators of 
pathology.  The heterogeneity of astrocytes may, in part, explain their diverse functions 
which include the uptake of ions, glutamate, glycine, glucose and water from the 
microenvironment as well as the release of growth factors, energy substrates, cytokines 
and chemokines.  In the context of HIV-1 or other insults, the normal function of 
astrocytes in providing and maintaining homeostasis and BBB integrity through 
structural and metabolic support is disrupted, resulting in deleterious implications.   
Similar to neurons, these cells of neuroectodermal origin were once suggested to be 
resistant to HIV-1 infection. However, recent studies have shown that astrocytes can 
indeed become infected under certain conditions [15-18].  Following infection and/or 
exposure to viral proteins released from neighboring infected cells, astrocytes release 
cytokines, chemokines and growth factors that are toxic for neurons and other 
neighboring cells in the CNS, thus providing an important reservoir for the generation of 
inflammatory mediators. Although astrocytes do not support productive viral replication, 
early HIV-1 genes such as Tat, Rev and Nef [19, 20] are expressed by these cells. It 
has been well documented that exposure of astrocytes to HIV-1 Tat protein results in 
their activation and release of toxic mediators [20] highlighting the critical role these 
cells play in amplifying neuroinflammation. 
Because the severity of HAND correlates with the presence of activated glial cells 
rather than with the viral load in the brain [21] it is critical to understand the immune 
capabilities and consequences of immune activation in astrocytes. Once activated by 
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infection, insult (exposure to toxic proteins) or injury, these cells undergo astrogliosis, an 
initial protective response characterized by cellular proliferation [22]. Additionally, a 
number of molecular and functional changes including the release of a myriad of 
cytokines and chemokines also accompanies activation [23, 24]. Astrogliosis is actually 
a well-meant protective response by the host to a toxic insult. However, because HIV-1 
proteins persist in the CNS, this well-meant acute response becomes sustained and 
prolonged, thereby manifesting as a double edged sword, leading to chronic cellular 
activation with the release of pro-inflammatory mediators. This, in turn, leads to 
increased neuronal injury, thus turning astrogliosis into a pathological feature of HAND. 
While astrocytes are non-productively infected to a limited extent with HIV, the sheer 
number of astrocytes in the brain has far-reaching implications in the CNS.   
HIV-1 Transactivator of Transcription (Tat) 
HIV-1 transactivator of transcription (Tat) protein was identified primarily due to 
its role in trans activation of the long terminal repeat (LTR) in Human T-cell leukemia 
Virus (HTLV)-infected cells [25, 26]. Since its discovery, extensive research has been 
ongoing to understand its activity and function in cells.  The basic region of Tat binds a 
transactivation responsive region (TAR) on the virus, recruiting a positive elongation 
factor b (P-TEFb) complex, which includes cyclin-dependent kinase 9 (CDK9) and cyclin 
T1, to the promoter region of the virus LTR resulting in efficient elongation of the viral 
transcript [27, 28]. Tat is encoded by two exons and due to splicing variation, exists 
predominantly in two lengths 1-86 and 1-101 in vivo [29]. However, because the first 
exon 1-72 is sufficient for transactivation in vitro [29], Tat 1-72 is also commonly used in 
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toxicity studies [30-34].  Although this project also included Tat lengths 1-86 and 1-101, 
Tat 1-72 is the primary form of Tat utilized for cell culture studies.    
An interestingly advantageous characteristic of Tat is not only its ability to be 
secreted from infected cells, but rather the diverse ways in which it can be taken up by 
neighboring cells to modulate cellular function. The arginine-rich RKKRRQRRR domain 
of Tat not only allows it to traverse across cell membrane but also contains the nuclear 
localization signal targeting it to the nucleus to transactivate the HIV-1 transcription 
genes [35]. In addition to crossing the plasma membrane, Tat can also bind to a number 
of cell surface proteins including viral co-receptor CXCR4, integrins, cell surface 
lipoprotein heparin sulfate proteoglycans (HSPG) and low density lipoprotein receptor-
related protein (LRP) [35].  The binding of Tat to these cell surface receptors triggers 
various cell signaling pathways depending upon the cell type and other factors leading 
to activation of the cell.  
In addition to activating transcription, other roles of Tat have now come to light. 
Several studies have suggested that Tat plays a role in neurotoxicity [36-39].  This 
direct neurotoxic effect of Tat is further compounded by the ability of Tat to also 
indirectly cause neuronal dysfunction/death by modulating the release of toxic 
substances from glial cells. For example, it has been shown that intraventricular 
injection of Tat results in prominent glial cell activation with subsequent infiltration of 
blood borne monocytes [40]. Tat exposure can also impact glial cell function by 
stimulating the production of pro-inflammatory cytokines [41, 42]. In fact, several cell 
culture studies have suggested that exposure of astrocytes to Tat protein leads to 
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astrocyte activation with the induction of cytokines and chemokines [20, 43, 44]. 
Significant among these are tumor necrosis factor-α (TNF-α), monocyte 
chemoattractant factor-1 (MCP-1)/CCL-2, and CXCL10 [45-48]. These findings have 
tremendous clinical implications since it is becoming increasingly appreciated that the 
severity of HAD/HIVE correlates more closely with the presence of activated glial cells 
rather than with the presence and amount of HIV-infected cells in the brain [2, 8, 9]. 
Thus HIV-1 Tat by its ability to activate astrocytes, the predominant cell types in the 
CNS, can actually lead to amplification of toxic responses in the CNS.  
Role of Platelet-Derived Growth Factor (PDGF) in HAND 
PDGF was originally identified as a potent mitogen in fibroblasts [49] and smooth 
muscle cells [50] however other functions of the PDGF family are rapidly emerging.  
PDGFs are a family of proteins comprising of four chains (A-D) encoded by four genes 
located on different chromosomes, that are highly conserved throughout the animal 
kingdom [51]. These proteins are usually expressed as dimers; PDGF-A and PDGF-B 
that can form homodimers or heterodimers, while PDGF-C and D only form 
homodimers. For the sake of clarity, PDGF (A-D) refer to the RNA expression whereas 
PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD refer to the protein expression of these 
genes. All four PDGF ligands exert their effects via tyrosine kinase receptors PDGF-Rα 
and PDGF-Rβ [52].  Members of this family are disulfide-bonded polypeptides that play 
critical roles in kidney, cardiac, blood vessel and placental development [51, 53].  The 
mitogenic and angiogenic properties of PDGF are now being capitalized upon in clinical 
applications to speed tissue recovery and wound healing and more recently are also 
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being examined for bone repair [54-57]. Despite their obvious beneficial role in tissue 
repair, recent studies have shed an alternative light on PDGF function. PDGF signaling 
has been implicated in a number of pathological disease including liver, lung and 
cardiac fibrosis, atherosclerosis, restenosis, pulmonary hypertension, cancer, gliomas 
and stroke [51, 58-62]. Its role in HIVE/HAND however, specifically as it pertains to 
astrogliosis has not been elucidated.  
In a previous study, we had investigated the association of PDGF-B and HIVE in 
rhesus macaques infected with the chimeric SIV/HIV (SHIV).  In this study, PDGF 
expression was primarily localized in cells around the blood vessels. The functional role 
of PDGF-BB in HAND however, remains unclear. To this end, this project was 
undertaken in an attempt to determine the role of PDGF-BB in HAND specifically as it 
pertained to astrocytic function and BBB breakdown. We hypothesize that excess 
astrocyte activation leads to astrogliosis and proinflammatory chemokine/cytokine 
release, hallmark features of HAND. 
Role of Monocyte Chemoattractant Protein 1 (MCP-1) in HAND 
Monocyte Chemattractant Protein 1 (MCP-1) also known as Chemokine –CC 
motif ligand 2 (CCL2) is a small 14kDa protein member of the CC chemokine family 
which plays a key role in mediating leukocyte transmigration across the BBB via binding 
to its cognate receptor CCR2. A number of studies have implicated MCP-1 in the 
pathogenesis of HAND [63-65]. The recruitment of inflammatory cells to the site of injury 
is a critical component of for resolution of disease pathogenesis, however, when there is 
a sustained level of MCP-1 driving a persistent transmigration of leukocytes into the 
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brain, glial activation ensues leading to tipping of the balance, from a much needed 
physiological response to a pathological one.  Enhanced MCP-1 levels have been 
correlated with a number of disease conditions including renal dysfunction, multiple 
sclerosis (MS), liver disease and AIDS [65-67]. Moreover, MCP-1 has been shown to 
correlate with increased HIV replication [68] thereby underscoring the functional role 
that MCP-1 may play in accelerating HIV. 
 In a previous study, we observed a positive correlation between expression of 
MCP-1 in the brain and neuropathological changes in rhesus macaques infected with 
chimeric SHIV [69]. However, the mechanism of induction of MCP-1 in the brains of 
HIV-infected patients remains poorly characterized. It has been shown that the HIV-1 
protein Tat significantly induces the expression of MCP-1 in astrocytes [65]. Moreover, 
our findings also demonstrate that Tat up-regulates PDGF-BB a known inducer of MCP-
1. This finding forms the basis of the second part of our studies. The data presented 
herein reveal that PDGF-BB exposure of astrocytes resulted in enhanced expression of 
MCP-1. Based upon previous evidence that MCP-1 alters BBB integrity and recruits 
monocyte transmigration into the brain, we rationalize that MCP-1 produced in excess 
by PDGF-BB-exposed astrocytes, can in turn, lead to increased transmigration of 
monocytes across the BBB, a hallmark feature of HIV-associated neuroinflammation. 
Early Growth Response Gene 1 (Egr-1) 
The zinc-finger transcription factor early growth response 1 (Egr-1) also known 
as Krox24, Zif 268, NGFI-A, TIS8  was originally identified as a serum-inducible zinc-
finger nuclear protein and predominantly known for its roles in neuronal plasticity and 
development [70, 71].  Egr-1 belongs to the Immediate Early Gene (IEG) family, which 
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also includes c-fos, fra1, fra2 and fos B [72] that can be induced without de novo protein 
synthesis allowing for rapid and transient induction by a number of growth factors, 
cytokines and stress signals [73].  The physiological role of Egr-1 is unknown, however 
the rate at which Egr-1 can be induced and its ability to be induced by a number of 
molecules has led others to suggest a potential function for this factor in the adult CNS 
[74-76]. Moreover, studies involving the interruption or deficiency of Egr-1 have 
demonstrated its involvement in learning and memory [76-78].  
Although the physiological role of Egr-1 remains enigmatic, the pathological role 
of Egr-1 is rapidly evolving. Egr-1 binds to specific Egr-response elements (EREs) in the 
promoter region to modulate the transcription of target genes [79].  Studies suggest that 
Egr-1 primarily functions as a suppressor [77, 80, 81], however, Egr-1 can activate the 
transcription of several genes implicated in HIV pathogenesis including PDGF , MCP-1 
and ICAM [77, 82-85]. 
NF-κB signaling 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a factor 
involved in activating the transcription of target genes and since its discovery research 
has been undertaken to better understand its activity and regulation.  NF-κB exists in a 
bound state sequestered by an inhibitory protein, Iκ-B.  Upon stimulation by a vast 
number of factors including HIV-1 Tat, Iκ-Bα is rapidly phosphorylated, ubiquinated and 
degraded releasing the transcriptionally active NF-κB p65 subunit to the nucleus where 
it can bind the promoter region and activate transcription.  Due to the vast number of 
target genes that can be activated by NF-κB, it has been implicated in a number of 
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cellular responses particularly immune response and inflammation.  Our findings 
implicate the role of NF-κB in mitigating MCP-1 released from astrocytes exposed to 
PDGF-BB.   
Blood-brain barrier (BBB) disruption in HAND 
The integrity of the BBB plays an important role in maintaining a safe neural 
microenvironment in the brain. BBB normally functions as an interface between the 
blood and brain parenchyma, acting as a watch guard to inhibit the entry of ions, 
molecules and infiltrating cells into the CNS. The presence of interendothelial adherens 
junctions (AJ) and tight junctions (TJ) between endothelial cells (EC) and EC-astrocytes 
maintain barrier properties [86]. During the normal immune surveillance, lymphocytes 
and monocytes cross into the CNS with little or no effect on BBB integrity. However, 
during progressive HIV-1 infection, there is a breach in this barrier [87-90] leading to 
influx of inflammatory cells into the brain resulting in clinical and pathological 
abnormalities, ranging from asymptomatic cognitive impairment to frank dementia. 
Previous studies have demonstrated that HIV-1 infected cells can disrupt an in vitro 
model of the BBB, which was supported by in vivo evidence depicting areas of BBB 
disruption found in regions enriched with activated, infected monocytes/macrophages, 
thereby leading to the speculation that infected cells themselves could disrupt the BBB.  
BBB plays a central role in the development of HAND because it serves as the 
conduit by which free virus and infected immune cells enter the brain from the 
circulatory system [23-25]. BBB compromise in neuropathogenesis of HIV-1 infection is 
substantiated by a number of laboratory, animal models and human studies 
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demonstrating BBB breakdown as a consequence of progressive viral infection and 
immune compromise [26-30]. Structurally, the BBB is composed of specialized 
nonfenestrated human brain microvascular endothelial cells (HBMECs) connected by 
intercellular junctions in an impermeable monolayer devoid of transcellular pores. 
Intercellular junctions are involved in regulation of integrity of the brain vascular 
endothelium and the BBB function.  
Although the mechanisms of BBB disruption during HIV-1 infection still remain 
unclear yet, alterations in TJ expression have been reported to contribute, at least in 
part, to this disruption. Hence down modulation of these tight junction proteins could be 
considered an indicator of the BBB breach. In brain microvascular endothelial (BMEC) 
cells it has been shown that Tat treatment resulted in decreased expression and/or 
distribution of the TJ proteins, claudin-1, claudin-5, and zonula occludens (ZO)-2. 
Decreased claudin-5 expression was further confirmed in vivo in mice that were 
administered Tat into the right hippocampus [91].  Mechanisms underlying Tat-mediated 
alteration of TJs involved redox-responsive signal transduction pathways, such as 
VEGFR-2/Ras/ERK1/2 pathway, PI3K/Akt/NF-κB pathway and calcium-dependent 
signaling [92]. Tat-mediated altered expression of both claudin and ZO-1, -2 could have 
a significant effect on vascular permeability since claudins are believed to be essential 
for the structural and functional maintenance of the TJ of BBB and also since ZO-1 
proteins mediate interactions of claudins with the actin cytoskeleton and stabilize the 
claudins in the membrane.  
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Our findings demonstrate that exposure of rat and human astrocytes to HIV Tat 
protein resulted in induction of PDGF-B RNA and protein levels.  PDGF-B chains once 
released can dimerize to form PDGF-BB protein. To determine the functional 
implications of PDGF-BB production, human astrocyte and HMBECs were exposed to 
PDGF-BB.  Rationale for using HBMECs is based on the premise that astrocytes are 
known to be present in close proximity to cells of the brain endothelium in the 
neovascular unit. Our findings suggest that exposure of astrocytes to PDGF-BB results 
in astrogliosis (increased astrocyte activation) as well as release of the chemokine 
MCP-1, the two hallmark features of HAND [63-65].  To further understand the 
implications of these findings and to explore the role of PDGF-BB in HIV 
neuropathogenesis, our central hypothesis is that exposure of astrocytes to viral protein 
Tat, results in the release of PDGF-BB, which in turn, leads to enhanced astrogliosis 
and BBB breakdown.  The long-term goal of this study is to develop targets that 
can block Tat-mediated up-regulation of PDGF-BB as a therapeutic strategy for 
HAND. The following specific aims were designed to elucidate our hypothesis: 
1. Determine the molecular mechanisms involved in HIV-1 Tat mediated induction 
of PDGF-B chain in astrocytes. 
2. Dissect the PDGF-BB-mediated cell signaling mechanisms involved in astrocyte 
release of MCP-1. 
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Significance 
There is an estimated 33 million people worldwide living with HIV/AIDS [1]. 
Studies reveal that 60 percent of those infected have some level of HIV associated 
neurodegenerative syndrome, termed HAND is clinically characterized by behavioral, 
cognitive and motor abnormalities [93]. The inability of protease inhibitors to penetrate 
the BBB raises concerns that while cART may effectively control HIV-1 replication 
elsewhere in the body, replication could continue uncontrolled in the brain, ultimately 
fueling neurological disease. Thus, the development of therapeutic interventions for the 
prevention and treatment of HAND among those infected with HIV is of paramount 
importance. Astroglial activation and dysfunction are key factors mediating 
neuroinflammation, thus controlling the cascade of actions contributing to the disruption 
of neuronal homeostasis. Astrogliosis and MCP-1 expression are major features of 
HAND and our studies provide evidence that both these factors are a consequence of 
Tat-mediated induction of PDGF-BB in astrocytes. These findings are of clinical 
importance as understanding the molecular mechanisms of increased astrogliosis and 
neuroinflammation via chemokine secretion, can lead to effective development of 
therapeutic strategies aimed at curbing HAND. 
Innovations: 
1. HIV-1/Tat-mediated induction of PDGF in astrocytes has never been explored 
before. 
2. These studies will identify mechanisms involved in PDGF-mediated induction of 
the chemokine MCP-1 critical for neuroinflammation. 
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3. The proposed studies will examine the potential detrimental effects of PDGF on 
BBB, leading to increased influx of inflammatory cells in the CNS. 
The hypothesis was tested exploring the following questions: 
Question 1: What are the molecular mechanisms involved in HIV-1/HIV-1Tat-
mediated induction of PDGF-BB in astrocytes? This question is addressed in 
Chapter 3.  
Question 2: What are the functional implications of PDGF-BB up-regulation? This 
question is addressed in Chapter 4.   
Question 3: What are the molecular mechanisms involved in the effect of astrocyte-
released PDGF-BB on MCP-1 up-regulation and BBB integrity. This question is 
addressed in Chapter 5. 
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Chapter 2 
HIV-1 Tat mediated up-regulation of PDGF in astrocytes 
Abstract 
HIV-associated neurocognitive disorders (HAND) are estimated to affect almost 60% of 
HIV infected individuals. HIV-encephalitis (HIVE), the pathological correlate of the most 
severe form of HAND is often characterized by glial activation, cytokine/chemokine 
dysregulation, and neuronal damage and loss. However, the severity of HIVE correlates 
better with glial activation rather than viral load. Using the rhesus macaque model, it has 
been demonstrated that simian immunodeficiency virus encephalitis (SIVE) correlates 
with increased expression of the mitogen platelet-derived growth factor-B (PDGF-B) 
chain in the brain. The data therein demonstrate an up-regulation of PDGF-BB in cells 
exposed to HIV-1 LAI virus which was abrogated by heat-inactivating the virus. Further 
studies reveal that HIV-1 Tat up-regulated PDGF-B mRNA chain but changes in PDGF-
A and PDGF-C chains were not evident.  Furthermore, Tat preparations, Tat 1-72, Tat 
1-86 and Tat 1- 101 all up-regulated PDGF-BB.  The up-regulation of PDGF-BB by Tat 
was also validated in human primary astrocytes.  In an attempt to ascertain the time 
course of PDGF-B up-regulation, our results reveal a time dependent increase in RNA 
and protein PDGF-B levels in rat and human astrocyte cell lines C6B2 and A172 as well 
as human primary cells.  The increase in PDGF-BB was further confirmed in vitro by 
immunostaining.  Cumulatively, these data clearly demonstrate HIV-1 Tat-mediated 
induction of PDGF-BB in human astrocytes and underscores the role that astrocytes 
play in HAND.  
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Introduction 
In the present work, we utilized rat and human astrocytes to study the effects of 
Tat on rat and human astrocytes.  The data herein demonstrate that exposure of rat and 
human astrocytes to Tat resulted in the induction of PDGF at both the mRNA and 
protein levels.  Since PDGF is a known cerebrovascular permeant [94], the release of 
PDGF by astrocytes may have significant consequences including disruption of blood-
brain barrier(BBB). This is particularly important since astrocyte endfeet processes are 
in close contact with the endothelial cells of the BBB. Furthermore, PDGF expression 
could also enhance astrocyte activation. An understanding of PDGF-BB regulation and 
its inhibition may thus aid in the development of therapeutic intervention strategies for 
those suffering from HAND.  
Materials and Methods 
Materials 
Tat 1–72, 1–86, and 1–101 (supplied by Philip Ray, University of Kentucky) were 
used in these studies at a concentration of 200 ng/ml. Details of Tat production and 
purification have been published previously [95-97].  Control treatments included heat 
inactivated HIV-1 Tat and cells receiving no treatment. The concentration of Tat in the 
cerebral spinal fluid has been reported at 16 ng/ml [98]; however, the Tat concentration 
used in this in vitro study is generally accepted [99-103].  HIV-1 LAI virus propagated in 
stimulated PBMCs (supplied by Dr. Howard Gendelman, University of Nebraska 
Medical Center) was used in this study [104]. The rationale for using CXCR4 (X4)-tropic 
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virus was based on previous studies demonstrating astrocyte activation in response to 
X4 viruses [105, 106]. 
Cell culture and cell lines 
The human astrocytic cell line A172 (ATCC no. CRL-1620; American Type 
Culture Collection) was cultured as described previously [107]. Rat glioma C6B2 cells 
were obtained from Dr. Myron Toews (University of Nebraska Medical Center). Human 
primary astrocytes were obtained from the Congenital Defects Lab (University of 
Washington). Rat primary astrocytes were isolated from embryonic day 18–19 Sprague-
Dawley rats (Charles River Laboratories, Wilmington, MA). Cortical tissues were 
dissected in HBSS and trypsinized. Cells were pelleted, plated, and sustained in CO2 
incubator at 37°C for 7 d. The cells were then shaken t o remove loosely attached cells. 
Attached cells that remained, primarily astroglia, were allowed to grow for 3–4 d and 
then passaged and seeded. Seven days after plating, cultures consisted of 97% 
astroglia. C6B2 immortalized cell line and rat primary astrocytes were cultured in DMEM 
medium (Invitrogen Life Technologies, Carlsbad, CA) containing 10% heated-
inactivated FBS, 2 mM glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml). 
Human primary astrocytes were cultured in DMEM medium (Invitrogen Life 
Technologies) containing 10% heat-inactivated FBS, 2 mM glutamine, sodium 
bicarbonate, gentamicin, nonessentialamino acids, and vitamins. 
 
Reverse transcription and real-time PCR 
Total RNA was extracted using Trizol reagent according to the manufacturer’s 
protocol (Invitrogen Life Technologies); 1 µg of RNA was used for cDNA production 
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according to manufacturer’s instructions (Thermo Scientific, Waltham, MA). Real Time 
RT2 qPCR primer sets for rat PDGF-A, PDGF-B, PDGF-C and 18s and human PDGF-B 
and 18s were obtained from SA Biosciences (Frederick, MD). Quantitative analyses of 
mRNA were conducted using ABI 7500 Fast Real-Time PCR system (Applied 
Biosystems, Foster City, CA). Data were normalized using the cycle threshold (Ct) 
values for 18s or GAPDH in each sample. To calculate relative amounts mRNA, the 
average Ct values were subtracted from 18s or GAPDH values for each target gene to 
provide changes in Ct value. Fold change in expression was calculated as log2 relative 
units. 
 
Western blotting 
Treated cells were lysed using the Mammalian Cell Lysis kit (Sigma, St. Louis, 
MO). Cell lysates were subjected to separation by 12% SDSPAGE electrophoresis (30 
mg protein per well) and transferred to polyvinylidene difluoride membranes. The blots 
were blocked with 5% nonfat dry milk in PBS. Western blots were then probed with Abs 
recognizing PDGF-BB (1:1000), β-actin (1:5000; Santa Cruz Biotechnology, 
Santa Cruz, CA) then incubated with goat–anti-rabbit secondary Ab (1:5000; Invitrogen 
Life Technologies). Signals were detected by chemiluminescence (Pierce, Rockford, IL). 
All experiments were repeated four times individually and representative blots are 
presented in the figures. 
 
Immunofluorescence labeling and image analyses 
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Immunocytochemical analysis of PDGF-BB were performed on rat glioma cells 
grown on cover slips. After Tat treatment, cells were fixed with 4% paraformaldehyde for 
15 min at room temperature and then permeabilized with PBS containing 0.3% Triton X 
100. After blocking with PBS containing 10% normal goat serum, cells were incubated 
at 4°C overnight with anti-PDGF-BB (1:200) rabbit p olyclonal Abs (Santa Cruz 
Biotechnology). After washing, cells were incubated with goat anti-rabbit Alexa Fluor 
488-conjugated secondary Ab (1:500). For negative controls, cells were treated as 
described above, but the primary Ab was omitted. Cells were mounted with Prolong 
Gold containing DAPI to stain nuclei. Images were captured with a 40X objective. 
Slide specimens (5 mm thick) of paraffin-embedded, SIV-infected rhesus 
macaque and HIV-1–infected human basal ganglia (National NeuroAIDS Tissue 
Consortium) were selected and treated with paired combinations of primary mouse and 
rabbit Abs anti-PDGF-BB (1:50; Santa Cruz Biotechnologies), PDGF-BB (1:1000; 
PGF007, Mochida, Tokyo, Japan), anti-von Willebrand factor (vWF; 1:00; Chemicon, 
Billerica, MA) and anti-glial fibrillary acidic protein (GFAP) (1:50) Abs (Santa Cruz 
Biotechnologies). Primary Abs were labeled with secondary anti-mouse and anti-rabbit 
Abs conjugated to the fluorescent probes Alexa Fluor 488 and Alexa Fluor 594, and 
nuclei were labeled with DAPI. Slides were covered with a coverslip with ProLong Gold 
antifade reagent (Invitrogen, Carlsbad, CA) and allowed to dry for 24 h at room 
temperature. Images were captured with a 20X objective. 
 
Statistical Analysis 
Statistical analysis was performed using one-way ANOVA with a post hoc 
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Student t test. Results were judged statistically significant if p < 0.05 by ANOVA. 
 
Results 
Because astrocytes in the CNS are exposed to HIV-1, we first sought to examine 
the modulation of PDGF-BB by HIV-1 exposure in astrocytes. Serum-starved human 
astrocyte cell line A172 was infected with HIV LAI at an multiplicity of infection of 0.1 for 
12 h followed by assessment of cell lysate for PDGF-BB expression by Western blot. As 
shown in Fig. 1 there was HIV-1–mediated up-regulation of PDGF-BB in cells exposed 
to the virus, and heat inactivated virus failed to mediate induction of PDGF-BB.  
Having determined the effect of whole virus on inducing PDGF-BB expression, 
the next step was to assess whether viral transactivator protein Tat, which is produced 
by both infected astrocytes and released from neighboring infected CNS cells, could 
also mediate this effect. Rat primary astrocytes were serum starved overnight followed 
by treatment with recombinant Tat (200 ng/ml) for 3 or 6 h. As an initial screen to 
identify which PDGF chains were expressed in response to Tat, mRNA levels of PDGF-
A, PDGF-B, and PDGF-C chains were determined by real-time PCR. After exposure of 
rat astrocytes to Tat for 3 and 6 h, there was up-regulation of PDGF-B mRNA (2.15- and 
3.2-fold respectively), compared with the untreated cells. As expected, heated Tat had 
no effect on the induction of PDGF-B mRNA. In contrast to PDGF-B, no significant 
changes in the mRNA levels of PDGF-A and PDGFC were evident (Fig. 2). Because 
only PDGF-B chain was up-regulated in response to Tat, further studies were focused 
only on the PDGF B chain. Similar to Tat 1–72, both Tat 1–86 and the full length Tat 1–
101 also mediated induction of PDGF-BB in human A172 cells (Fig. 3A). Validation of 
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our findings in the human astrocyte cell line was also confirmed in human primary 
astrocytes (Fig. 3B). 
To assess the time course of Tat-mediated induction of PDGF-B, rat and human 
astrocyte cell lines (C6B2 and A172) as well as rat primary astrocytes were treated with 
Tat (200 ng/ml) for varying times (5 min to 6 h), followed by RNA extraction and 
assessment of PDGF-B chain mRNA levels by real-time PCR. As shown in Fig. 4A, 
PDGF-B mRNA was up-regulated in a time-dependent manner in all the cell types 
examined, with a peak expression at 3–6 h. To examine whether the mRNA up- 
regulation translated into increased protein expression, all the cell types were treated as 
described above, followed by cell lysis and Western blotting. Because PDGF-BB is an 
early response protein, we also chose earlier time points for detection. As shown in Fig. 
4B, Tat up-regulated PDGF-BB protein expression in a time-dependent manner with a 
peak expression at 6 h and a decline thereafter. PDGF-BB expression in rat astrocytes 
appeared to peak earlier (3 h) compared with its expression in the cell lines (6 h). 
Confirmation of these findings by immunostaining also revealed increased PDGF-BB 
expression in Tat-treated rat glioma cells at 6 h after treatment (Fig. 5). Images were 
captured with a 40X objective lens and fluorescence microscopy. Cumulatively, these 
data clearly demonstrate HIV-1–Tat-mediated induction of PDGF- BB protein in rat and 
human astrocytes. 
To validate PDGF-BB expression in SIV or HIV infection, paraffin-embedded 
sections of basal ganglia from SIV-infected rhesus macaques with (SIVE) and without 
encephalitis were stained for PDGF-BB, an endothelial cell marker, von Willebrand 
Factor (vWF), and GFAP. As shown in Fig. 6A, there was up-regulated expression of 
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PDGF-BB in astrocytes surrounding the blood vessels in brains of macaques with SIVE 
(lower panels) compared with the infected animals without encephalitis (upper panels). 
In addition to being a marker for endothelial cells, Liu and colleagues have 
demonstrated that enhanced vWF immunoreactivity was associated with loss of BBB 
integrity in the spinal cords of mice with Experimental autoimmune encephalomyelitis 
(EAE) [108]. These findings, coupled with the fact that gliotic reactions around blood 
vessels were observed, raise the possibility that vWF immunoreactivity present in HIV 
and SIV-infected basal ganglia tissues may also reflect a leaky endothelial barrier. 
 Similar studies were performed on basal ganglia sections from human subjects 
with HIVE and uninfected controls. As shown in Fig. 6B, there was increased 
expression of astrocytic PDGF-BB in the sections from HIVE versus uninfected controls. 
Images were captured with a 20X objective lens and fluorescence microscopy. 
 
Discussion 
Anti-retroviral therapies have proved highly effective in controlling systemic viral 
infection, thus leading to increased longevity in patients with AIDS. The inability of some 
of these drugs to cross the blood-brain barrier results in slow and smoldering infection in 
the CNS. Subsequently, the brain becomes a sanctuary of virus induced toxicity leading 
to increased prevalence of HAND in HIV-infected individuals. One of the hallmark 
features of HAND is increased astrogliosis comprising increased numbers of activated 
astrocytes, culminating ultimately into increased neuronal dysfunction/degeneration. It is 
well recognized that activation of astrocytes leads to the release of a plethora of 
inflammatory cytokines and chemokines as well as factors such as PDGF-BB. PDGF-
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BB has been implicated in a variety of pathologic conditions; however, its role in HIV 
pathogenesis remains poorly defined. 
PDGF-BB has been shown to be up-regulated in the brains of macaques with 
SIVE [109]. It belongs to a family of five dimeric ligands (PDGF-AA, -AB, -BB, -CC, and 
-DD) assembled from four gene products (PDGF-A, -B, -C, and -D) that act through two 
classical receptor-tyrosine kinases, PDGF-αR and PDGF-βR [51, 60, 109, 110].  
HIV Tat protein that is released from HIV-infected cells is often taken up by the 
neighboring cells in the CNS. It has been previously reported that Tat-expressing 
astrocytes caused astrocytosis, astrocyte dysfunction, and subsequent neuronal death 
[37], suggesting that both astrocyte dysfunction and certain factors induced by HIV-
1/HIV-Tat may contribute to neurotoxicity. Because astrocytes, the most abundant cells 
within the CNS play a key role in the pathogenesis of HAND via the release of 
proinflammatory cytokines, chemokines, and other toxic mediators, this study was 
undertaken to explore the role of yet another mediator, PDGF-BB that is released by 
astrocytes in response to HIV-1 or HIV-1 Tat. We demonstrate that exposure of HIV 
1/Tat to rat and human astrocyte cell lines as well as rat primary astrocytes resulted in 
the induction of PDGF at both the transcriptional and translational levels. 
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Figure 1 
 
Figure 1: HIV-mediated induction of PDGF-BB in human A172 astrocytes. Cells were 
either treated with HIV LAI virus or heat inactivated HIV LAI virus at a multiplicity of 
infection 0.1 for 12 hours.  Whole cell lysates were subjected to Western Blott analysis 
using antibodies specific for PDGF-BB. The data are presented as mean ± SD of three 
individual experiments. ***p < 0.001 versus control group, ### p < 0.001 versus HIV-
treated group. 
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Figure 2 
 
 
Figure 2: HIV-1 Tat-mediated induction of PDGF-B mRNA in human A172 astrocytes. 
Cells were either treated with HIV Tat 200ng/ml for 3 and 6hours.  Total RNA isolated 
from primary rat astrocytes was subjected to real-time PCR analysis using primer sets 
for PDGF-A, PDGF-B, and PDGF-C primers. Tat-mediated induction of PDGF-B 
mRNA expression, but no changes in PDGF-A and PDGF-C were evident. Heated Tat 
abolished Tat-mediated induction of PDGF-B. The data are presented as mean ± SD of 
three individual experiments. *p < 0.05, **p <0.01 vs untreated control. 
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Figure 3 
 
 
Figure 3: HIV-1 Tat-mediated induction of PDGF-BB protein in human astrocytes. A,  
Human A172 cells were treated with 200ng/ml of Tat lengths 1–72, 1–86, and 1–101 
and PDGF-BB levels were assessed by Western blot analysis. B, Tat-mediated up-
regulation of PDGF-BB in human primary astrocytes. Whole cell lysates from human 
primary astrocytes treated with Tat for 12 h were subjected to Western blot analysis.  
The data are presented as mean ± SD of three individual experiments. **p <0.01, ***p < 
0.001 vs untreated control. 
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Figure 4 
 
 
 
 
Figure 4: Time dependence of Tat-mediated induction of PDGF-B mRNA and protein 
expression in rat primary astrocytes, rat gliomas, and human A172 cells. A, Total RNA 
isolated from rat primary astrocytes, rat gliomas, and human A172 cells were subjected 
to Real-time PCR analysis using primer sets for PDGF-B mRNA. B, Time dependence 
of Tat-mediated induction of PDGF-BB protein expression in rat primary astrocytes, rat 
gliomas, and human A172 cells. Whole cell lysates from rat primary astrocytes, rat 
gliomas, and human A172 cells were subjected to Western blot analysis using Abs 
specific for PDGF-BB.  The data are presented as mean ± SD of three individual 
experiments. *p < 0.05, **p <0.01, ***p < 0.001 vs untreated control. 
A 
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Figure 5 
Figure 5: Representative image of PDGF
magnification 400X). Rat glioma cells were treated with Tat (200ng/ml) for 6 hours 
followed by immunostaining using Abs specific for PDGF
using an 40X oil-immersion lens and fluorescent microscopy.
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Figure 6 
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Figure 6: A, Representative image of GFAP plus astrocytes expressing PDGF-BB 
surrounding the blood vessels (vWF positive) in the basal ganglia of SIV-infected rhesus 
macaques with or without SIVE (original magnification 200X). Images were acquired 
using a 20X lens and fluorescent microscopy. B, Representative image of GFAP plus 
astrocytes expressing PDGF-BB in the basal ganglia sections from humans with HIVE 
compared with uninfected (HIV-) controls (original magnification 200X). Images were 
acquired using a 20 lens and fluorescent microscopy. GFAP immunoreactivity was 
stained in red, PDGF-BB immunoreactivity was stained in green, and DAPI staining was 
performed to visualize the nuclei (blue). n = 3 per group. 
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Chapter 3  
Signaling Pathways involved in Tat-mediated up-regulation of PDGF in astrocytes 
Abstract 
We have previously shown that HIV-1 Tat modulates PDGF-BB in astrocytes. 
The present study was aimed at exploring the mechanisms involved in Tat-mediated 
PDGF-BB induction observed in astrocytes. Specifically, the data herein demonstrate 
that HIV-1 Tat activates ERK, JNK and p38 MAPKs as well as PI3k/Akt pathway, 
however further studies indicate that PDGF-BB induction was regulated by activation of 
ERK1/2 and JNK signaling pathways, but not P38 MAPK and PI3K/Akt pathways.  
Moreover, using pharmacological and genetic approaches we demonstrate that JNK 
and ERK was involved in the activation of the downstream transcription factor, early 
growth response 1 (Egr-1) in response to HIV-1 Tat.  Further studies using PDGF-βR 
siRNA transfected astrocytes, suggest that Egr-1 plays a critical role in the up-regulation 
of PDGF-BB in astrocytes exposed to HIV-1 Tat. Chromatin immunoprecipitation (ChIP) 
assays demonstrated increased binding of Egr-1 to the PDGF-B promoter validating the 
role of Egr-1.  These results map out a detailed pathway in which the exposure of 
astrocytes to Tat leads to enhanced PDGF-BB expression in astrocytes.  
Materials and Methods 
Materials 
The specific phosphatidinylinositol-39 kinase (PI3K) inhibitor (LY294002), MEK 
inhibitor (U0126), and p38 inhibitor (SB203580) were purchased from Promega 
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(Madison, WI). The JNK inhibitor (SP600125) was purchased from Assay Designs (Ann 
Arbor, MI). The concentrations of these inhibitors were based on the concentration-
curve study and our previous reports (22, 23). Dominant negative (DN) and 
constitutively active (CA) constructs of MEK (MAPK) and Egr-1 were provided by Dr. 
Young Han Lee (Konkuk University, Korea). Chromatin immunoprecipitation (ChIP) 
assay kit was purchased from Upstate (Billerica, MA). 
 
Reverse transcription and real-time PCR 
Total RNA was extracted using Trizol reagent according to the manufacturer’s 
protocol (Invitrogen Life Technologies); 1 mg of RNA was used for cDNA production 
according to manufacturer’s instructions (Thermo Scientific, Waltham, MA). Real Time 
RT2 qPCR primer sets for and human Egr-1 and 18s or GAPDH were obtained from SA 
Biosciences (Frederick, MD). Quantitative analyses of mRNA were conducted using ABI 
7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). Data were 
normalized using the cycle threshold (Ct) values for GAPDH in each sample. To 
calculate relative amounts mRNA, the average Ct values were subtracted from 18s or 
GAPDH values for each target gene to provide changes in Ct value. Fold change in 
expression was calculated as log2 relative units. 
 
Western blotting 
Treated cells were lysed using the Mammalian Cell Lysis kit (Sigma, St. Louis, 
MO), and cell lysates were subjected to separation by 12% SDSPAGE electrophoresis 
(30 ug protein per well) and transferred to polyvinylidene difluoride membranes. The 
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blots were blocked with 5% nonfat dry milk in PBS. Western blots were then probed with 
Abs recognizing Egr-1 (1:500), β-actin (1:5000; Santa Cruz Biotechnology, Santa Cruz, 
CA), and phosphorylated forms of ERK1/2, JNK, p38, and Akt (1:200; Cell Signaling, 
Danvers, MA). Cells were then incubated with goat–anti-rabbit secondary Ab (1:5000; 
Invitrogen Life Technologies). Signals were detected by chemiluminescence (Pierce, 
Rockford, IL). All experiments were repeated four times individually and representative 
blots are presented in the figures. 
 
Immunofluorescence labeling and image analyses 
Immunocytochemical analysis of Egr-1 were performed in rat glioma cells grown 
on cover slips. After Tat treatment, cells were fixed with 4% paraformaldehyde for 15 
min at room temperature and then permeabilized with PBS containing 0.3% Triton X-
100. After blocking with PBS containing 10% normal goat serum, cells were incubated 
at 4°C overnight with anti-Egr-1 (1:200) rabbit pol yclonal Ab (Santa Cruz 
Biotechnology). After washing, cells were incubated with goat anti-rabbit Alexa Fluor 
488-conjugated secondary Ab (1:500). For negative controls, cells were treated as 
described above, but omitting the primary Ab. Cells were mounted with Prolong Gold 
containing DAPI to stain nuclei. Images were captured with a 40X objective.  
 
Transfection with plasmid constructs 
A172 cells were transfected with plasmid constructs containing either wild type 
(WT) or dominant negative (DN) forms of MEK and Egr-1. Knockdown efficiencies were 
determined by Western blotting. 
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Short interfering RNA transfection 
Short interfering RNA (siRNA) targeting against Egr-1 were obtained from 
Dharmacon (Boulder, CO). Human A172 cells were plated in 24-well plates at a density 
of 4 X 104 cells per well 1 d prior to transfection. Cell culture medium was replaced with 
250 ml prewarmed culture medium. Dharma-FECT 1 transfection reagent (Dharmacon) 
was then combined with serum-free DMEM medium (Invitrogen Life Technologies) for 5 
min at room temperature. The Egr-1 siRNA was then added into the mixture described 
above to a final concentration of 5 mM. The siRNA and the reagent mixture were 
incubated for 20 min at room temperature, after which the combined mixture was added 
to the cells. The cell culture plate was shaken gently for 5 s and incubated for 48 h at 
37°C. Knockdown efficiencies were determined by Western blotting. 
 
Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay was performed according to the 
manufacturer’s instructions (Upstate) with slight modifications. After treatment of the 
cells, 18.5% fresh formaldehyde was added directly into the medium at a final 
concentration of 1% formaldehyde and incubated for 10 min at room temperature, 
followed by quenching with 125 mM glycine. The cells were then scraped using 2 ml 
prechilled PBS containing 1X protease inhibitor mixture. The cell pellet was harvested 
by spinning at 800 X g at 4°C, and lysis buffer was add ed (provided in the kit) to harvest 
nuclei. DNA was then sheared by sonication. Fifty microliters of the sheared cross-
linked chromatin was then mixed with 20 ml protein A magnetic beads and 5 mg 
immunopreciptating Abs against Egr-1, acetyl histone H3 (as a positive control), and 
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normal rabbit IgG (as a negative control) diluted in 450 ml dilution buffer overnight at 
4°C. The magnetic beads binding Ab–chromatin complex  was then washed with 0.5 ml 
each of a series of cold wash buffers in the order of low salt buffer, high salt buffer, LiCl 
buffer, and Tris-EDTA buffer. The cross-linking of protein–DNA complexes were 
reversed to free DNA by incubation at 62°C for 2 h an d purified using DNA purification 
spin columns following the manufacturer’s instructions. Finally, the purified DNA was 
amplified via PCR to identify the promoter region containing Egr-1 binding site “GCG 
GGG GCG.” The sequence of the primers used to identify the PDGF-B promoter bound 
to Egr-1 were as follows: sense, 59 GCAGAGGCCTGAGCGCCTGATC- 39; anti-sense, 
59-GCAGCGATTCATGCCGACTCCG-39. 
 
Results 
Having determined Tat-mediated induction of PDGF-BB, we sought to elucidate 
the signaling pathways involved in this process. Because Tat signaling involves MAPK 
pathways, we examined the involvement of ERK1/2, JNK, and p38 kinases in Tat-
mediated induction of PDGF-BB. Treatment of rat glioma cells with HIV-1 Tat resulted in 
a time-dependent increase in phosphorylation of ERK1/2, JNK, p38, and Akt, with 
maximal activation at 30 min after treatment (Fig. 7A). Specificity of these signaling 
pathways was subsequently assessed using a pharmacologic approach. Pretreatment 
of cells with MAPK (MEK) inhibitor U0126 resulted in abrogation of Tat-induced 
phosphorylation of ERK as expected, because MEK lies upstream of ERK1/2. However, 
pretreatment of cells with PI3K inhibitor LY294002 failed to inhibit ERK phosphorylation. 
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Conversely, treatment of cells with PI3K inhibitor resulted in the inhibition of Tat-induced 
activation of Akt, but not ERK1/2 (Fig. 7B). 
We next wanted to address the functional role of MAPK and PI3K/Akt in the 
PDGF-BB expression induced by Tat. Human A172 cells were pretreated with inhibitors 
specific for the respective signaling pathways prior to stimulation with Tat and assessed 
for expression of PDGF-BB. As shown in Fig. 8A, pretreatment of cells with MEK 
(U0126, 20 µM), JNK (SP600125, 20 µM), but not PI3K (LY294002, 10 µM) inhibitor, 
resulted in the amelioration of Tat-mediated induction of PDGF-BB. Pretreatment of 
A172 astrocytes with p38 inhibitor (SB203580, 10 µM) also did not result in the 
amelioration of PDGF-BB expression in response to Tat (Fig. 8B). Further validation of 
the involvement of ERK pathway in this process was confirmed by transfecting cells with 
either the WT or DN constructs of MEK followed by treatment with Tat. Tat-mediated 
induction of PDGF-BB was attenuated by DN-MEK, but not by WT-MEK construct (Fig. 
8C). These findings confirm the involvement of ERK MAPKs, but not p38 and PI3K/Akt 
cascade in Tat-mediated induction of PDGF-BB in astrocytes. 
 
Egr-1 expression is up-regulated in astrocytes exposed to Tat  
Having determined the involvement of ERK1/2 and JNK MAPKs in Tat-mediated 
PDGF-BB expression and from published reports suggesting the binding of Egr-1 to 
PDGF-B promoter [82], we rationalized the involvement of Egr-1 in Tat-mediated 
induction of PDGF-BB. Exposure of astrocytes to Tat resulted in a time-dependent 
increase of Egr-1 expression both at the mRNA and protein levels in rat and human 
astrocyte cell lines (C6B2 and A172) as well as rat primary astrocytes. As shown in Fig. 
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9A, Egr- 1 mRNA was up-regulated in a time-dependent manner in all the cell types 
examined, with a peak at 15–30 min. To examine whether the mRNA up-regulation 
translated into increased protein expression, all the cell types were treated as described 
above, followed by Western blotting. As shown in Fig. 9B, Tat up-regulated Egr-1 
expression in a time-dependent manner with a peak expression between 1 and 3 h and 
a decline thereafter. Confirmation of these findings by immunostaining also revealed 
increased Egr-1 expression in Tat treated human A172 cells at 1 h after treatment (Fig. 
9C). Cumulatively, these data clearly demonstrate that Tat mediated the induction of 
Egr-1 expression in rat and human astrocytes.  
The next logical step was to examine whether there was a link that could tie 
together the activation of ERK1/2, JNK MAPKs, and PI3K/Akt with Egr-1. Similar to our 
studies on signaling molecules described above, astrocytes were pretreated with MEK, 
JNK, or PI3K inhibitors followed by Tat treatment. As shown in Fig. 10A, MEK and JNK 
inhibitors but not PI3K inhibitor ameliorated the Tat-mediated activation of Egr-1. These 
findings thus linked Tat-mediated activation of ERK1/2 and JNK to the downstream 
activation of Egr-1. 
Further validation of the involvement of ERK1/2 pathway in this process was 
confirmed by transfecting cells with either the WT or DN constructs of MEK followed by 
treatment with Tat. Tat-mediated induction of Egr-1 was attenuated by DN-MEK, but not 
by the WT-MEK construct (Fig. 10B). These findings underpin the involvement of MEK 
MAPKs, but not the PI3K/Akt cascade in Tat-mediated induction of Egr-1 in astrocytes. 
 
Involvement of Egr-1 in Tat-induced expression of PDGF-BB in astrocytes 
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Since Egr-1 is a transcription factor implicated in the induction of PDGF-BB, we 
next wanted to examine the expression kinetics of Egr-1 and PDGF-B mRNAs. As 
shown in Fig. 11, in both the cell lines and primary astrocytes, Egr-1 expression 
(peaking at 15–30 min) preceded that of the PDGF-B chain expression (peaking at 3–6 
h). 
To confirm the role of Egr-1 in Tat-mediated induction of PDGF-BB, knocking 
down the expression of Egr-1 using the siRNA approach was used. As shown in Fig. 
12A, transfection of human A172 cells with Egr-1 siRNA resulted in efficient knockdown 
of Egr-1 protein using Western blot assay. Furthermore, Egr-1 siRNA also significantly 
abrogated Tat-mediated up-regulation of PDGFBB expression (Fig. 12B). To further 
validate the involvement of the Egr-1 in Tat-induced regulation of PDGF-BB, cells were 
transfected with either WT or DN constructs of Egr-1, followed by treatment with Tat. 
Tat-mediated induction of PDGF-BB was attenuated by the DN–Egr-1 construct, but not 
by the WT–Egr-1 construct (Fig. 12C). Collectively, these findings thus underscore the 
role of Egr-1 in Tat-mediated induction of PDGF-BB. 
To further confirm the binding of Egr-1 with PDGF-B promoter in its natural 
chromatin context, we resorted to chromatin immunoprecipitation to reveal active sites 
accessible to Egr-1. Rat glioma cells were treated with Tat for 3 h followed by DNA 
extraction and processed using a ChIP analysis kit. These experiments revealed 
increased binding of Egr-1 to the PDGF-B promoter in rat glioma cells treated with Tat 
(Fig. 12D,E).  
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Discussion 
In our efforts to dissect Tat-mediated downstream signaling events, we 
demonstrated the activation of ERK1/2, JNK, p38 MAPK, and PI3K/Akt pathways by 
Tat. Further dissection of the signaling pathways involved in Tat-mediated induction of 
PDGF-BB using both the pharmacologic and genetic approaches revealed activation of 
ERK1/2, JNK, p38 MAPKs, and PI3K/Akt pathways. Despite the activation of all these 
pathways, Tat-mediated induction of PDGF-BB involved only the ERK1/2 and JNK, but 
not p38 and PI3K/Akt signaling.  
The transcription factor Egr-1 has emerged as a major regulatory transcription 
factor for a number of genes including growth factors such as PDGF [77, 83, 111]. Our 
findings demonstrated a time-dependent up-regulation of Egr-1 again at both the 
transcriptional and translational levels in rat and human astrocytes. Further dissection of 
Egr-1 regulation using both the pharmacologic and genetic approaches revealed the 
activation of upstream ERK1/2 and JNK MAPK pathways in the activation of Egr-1. In 
agreement with our findings, requirement of ERK1/2 and JNK activation for Egr-1 
expression has been reported in FGF2-treated astrocytes [112]. Considering that Egr-1 
is an early response gene that regulates a number of other target genes, it was of 
interest to examine its expression profile compared with that of PDGF-B expression. 
Interestingly, Egr-1 expression preceded that of PDGF-B, leading us to speculate their 
interaction. In an effort to determine a link between Egr-1 and PDGF-B expression, we 
demonstrated increase Egr-1 binding to the PDGF-B promoter in astrocytes treated with 
Tat, lending credence to the role of Egr-1 in PDGF-BB expression. Further support of 
Egr-1 involvement in Tat-mediated PDGF-BB induction was also demonstrated using 
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both the siRNA and genetic approaches. Our findings are in agreement with the report 
by Khachigan et al. [82], which demonstrated that Egr-1 interacts with the PDGF-B 
promoter in arterial endothelial cells. The role of Egr-1 in Tat-mediated dysfunction of 
astrocytes has recently been elegantly demonstrated by Fan et al. which revealed that 
Tat enhances Egr-1 by directly transactivating the Egr-1 promoter and that this 
interaction may be involved in the molecular events that initiate Tat-induced astrocyte 
dysfunction [113].  
We further elucidated that signaling mechanisms involved in PDGF-BB induction 
was regulated by activation of ERK1/2 and JNK signaling pathways and the 
downstream transcription factor, Egr-1.  ChIP analysis revealed increased binding of 
Egr-1 to the PDGF-B promoter in rat glioma cells treated with Tat.  Based upon our 
findings we propose molecular pathway of Tat-mediated induction of PDGF-BB 
schematically illustrated in Figure 13. 
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Figures 
Figure 7 
  
FIGURE 7. Tat up-regulates MAPK and Akt/PI3k pathways. A, Western blot analysis of 
time-dependent activation ERK1/2, JNK, p38, and Akt by Tat. B, ERK1/2 and Akt 
pathways are activated independently of each other. Pretreatment of cells with MAPK 
(MEK) inhibitor (U0126), resulted in abrogation of Tat-induced phosphorylation of 
ERK1/2. However, pretreatment of cells with PI3K inhibitor (LY294002) failed to inhibit 
ERK1/2 phosphorylation. Conversely, treatment of cells with PI3K inhibitor resulted in 
the inhibition of Tat-induced activation of Akt, but not ERK1/2. All data are presented as 
mean ± SD of three individual experiments. **p < 0.01, versus control group, #p < 0.05, 
##p < 0.01, ###p < 0.001 versus Tat-treated group. 
A B 
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Figure 8 
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Figure 8. ERK1/2 and JNK MAPK but not p38 and PI3K/Akt pathways are involved in 
Tat-mediated PDGF-BB expression in astrocytes.  A, Pretreatment of cells with MEK 
inhibitor (U1026) and JNK inhibitor (SB600125) resulted in the amelioration of Tat-
mediated PDGF-BB expression. Conversely, pretreatment with PI3K inhibitor 
(LY294002) failed to inhibit Tat-mediated PDGF-BB expression. B, Pretreatment of cells 
with p38 inhibitor (SB203580) did not ameliorate Tat-mediated induction of PDGF-BB. 
C, Transfection with DN-MEK and not WT-MEK resulted in abrogation of Tat-mediated 
induction of PDGF-BB. All data are presented as mean ± SD of three individual 
experiments. **p < 0.01, ***p < 0.001 versus control group, #p < 0.05, ##p < 0.01 versus 
Tat-treated group. 
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Figure 9. 
 
 
 
 
 
FIGURE 9. Egr-1 expression is up-regulated in astrocytes exposed to Tat. A, Time 
dependence of Tat-mediated induction of Egr-1 mRNA expression in rat gliomas and 
A 
B 
C 
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human A172 cell lines and rat primary astrocytes. B, Whole cell lysates from rat gliomas 
and human A172 cell lines and rat primary astrocytes were subjected to Western blot 
analysis using Abs specific for Egr-1. Time dependence of Tat-mediated induction of 
Egr-1 protein expression in rat gliomas and human A172 cell lines and rat primary 
astrocytes.  C, Representative picture of Egr-1 staining in rat gliomas. . *p < 0.05, **p 
<0.01 vs untreated control. 
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Figure 10. 
 
  
Figure 10. MAPK but not Akt/PI3k is involved in Tat-mediated induction of Egr-1. A, 
Inhibition of the ERK1/2 and Akt pathways by MEK (U0126) and PI3K inhibitor 
(LY294002) resulted in amelioration of Tat-mediated Egr-1 expression. B, Transfection 
with DNMEK and not WT-MEK resulted in abrogation of Tat-mediated induction of Egr-
1.  **p <0.01 vs untreated control,  ###p < 0.001 versus Tat-treated group. 
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Figure 11. 
 
 
 
 
 
 Figure 11. Kinetic profiles of Egr-1 and PDGF-B mRNA levels in rat primary astrocytes, 
rat gliomas and human A172 cells. Egr-1 expression preceeds PDGF-B expression 
suggesting the involvement of Egr-1 in Tat-induced expression of PDGF-BB in 
astrocytes. 
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Figure 12 
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Figure 12. Involvement of Egr-1 in Tat-induced expression of PDGF-BB in Astrocytes. 
A, Whole-cell lysates from A172 cells transfected with either Egr-1 or Nonsense (Non) 
siRNAs were subject to Western blot analysis using Abs specific Egr-1. B, Egr-1 siRNA, 
but not nonspecific siRNA, inhibited HIV-1 Tat-mediated induction of PDGF-BB 
expression. C, Whole-cell lysates from A172 cells transfected with either WT or DN 
forms of MEK were subjected to Western blot analysis using Abs specific Egr-1. DN-
MEK, but not WT-MEK, inhibited Tat-mediated induction of PDGF-BB expression. D, 
Schematic illustration of Egr-1 binding consensus sequence on the PDGF-B promoter 
region. E, ChIP assay demonstrating Tat-mediated binding of Egr-1 to the PDGF-B 
promoter. All data are presented as mean ± SD of three individual experiments. **p < 
0.01, *** p < 0.001 versus control group. 
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Figure 13 
 
 
 
 
 
 
 
 
 
 
Figure 13. Schematic of the signaling pathways involved in the increased induction of 
PDGF-BB in astrocytes stimulated with Tat. Tat-mediated activation of ERK1/2, JNK, 
p38 MAPKs, and PI3K/Akt signaling pathways. ERK1/2 and JNK MAPKs but not and 
PI3K/Akt and p38 signaling resulted in the subsequent activation of the downstream 
transcription factor, Egr-1. Activation of Egr-1 in turn leads to enhanced PDGF-BB 
expression as shown in Figure 13. 
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Chapter 4: Functional Implications of PDGF-BB up-regulation 
Abstract 
We have previously shown that HIV-1 Tat modulates PDGF-BB in astrocytes. 
The present study was aimed at exploring the role of PDGF-B chain in HIV-associated 
activation and proliferation of astrocytes. 
PDGF-BB, released from Tat-treated astrocytes resulted in both increased 
proliferation and release of pro-inflammatory cytokines MCP-1 and IL-1β in astrocytes. 
Since astrogliosis is linked to disease severity, understanding its regulation by PDGF-
BB and its relationship with MCP-1 could aid in the development of therapeutic 
intervention strategies for HAND. 
Materials and Methods 
Reverse transcription and real-time PCR 
Total RNA was extracted using Trizol reagent according to the manufacturer’s 
protocol (Invitrogen Life Technologies); 1 mg of RNAwas used for cDNA production 
according to manufacturer’s instructions (Thermo Scientific, Waltham, MA). Real Time 
RT2 qPCR primer sets for rat PDGF-βR and GAPDH and human PDGF-βR, MCP-1, IL-
1β 18s and GAPDH were obtained from SA Biosciences (Frederick, MD). Data were 
normalized using the 18s or GAPDH amounts in each sample.  To calculate relative 
amounts mRNA, the average Ct values were subtracted from 18s or GAPDH values for 
each target gene to provide changes in Ct value. Fold change in expression was 
calculated as log2 relative units. 
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Assay for cell viability 
Cell viability was measured by mitochondrial dehydrogenases (i.e., MTT) 
method. Human A172 and rat glioma cells were seeded in 96-well plates at a density of 
1X105 cells/cm2 and were exposed to PDGF-BB for 4 d. After incubation, 20 µl MTT salt 
dissolved in HBSS at a final concentration of 5 mg/ml was added to each well for 4 h. 
The medium was aspirated from each well, and 200 µl DMSO was added to dissolve 
the formazan crystals. The absorbance of each well was obtained using a Synergy Mx 
(BioTek) plate counter at test and reference wavelengths of 570 and 630 nm, 
respectively. 
 
Results 
PDGF-BB induces cell proliferation and proinflammatory cytokine expression in 
astrocytes 
Having determined the induction of PDGF-BB by Tat, this study was undertaken 
to explore the functional relevance of this up-regulation. Because PDGF-BB is a known 
mitogen for various cell types, we hypothesized that Tat-induced PDGF-BB released 
from the astrocytes could act on the astrocytes themselves via an autocrine loop. We 
set out to examine the effect of PDGF-BB on both proliferation and expression of 
proinflammatory cytokines in these cells; however, before proceeding with this, it was 
important to first examine whether astrocytes indeed expressed the PDGF-βR. As 
shown in Fig. 14A, rat glioma and human astrocyte cell lines (C6B2 and A172) as well 
as rat primary astrocytes cells expressed PDGF-βR mRNA as demonstrated by RT-
PCR. The effect of PDGF-BB on astrocyte proliferation demonstrated a significant 
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increase in cell proliferation, as evidenced by MTT assays in both rat glioma and human 
A172 cells (Fig. 14B).  
In addition to proliferation, astrocytes also respond to activation by releasing a 
plethora of cytokines and chemokines. To further elucidate the role of PDGF-BB in this 
process, and because it is a known inducer of the chemokine MCP-1 [114], we next 
examined the effect of PDGF-BB on the induction of MCP-1 and the pro-inflammatory 
cytokine IL-1β in A172 cells. As shown in Fig. 14C, treatment of human A172 cells with 
PDGF-BB resulted in a dramatic up-regulation of MCP-1 and a significant induction of 
IL-1β as measured by real-time PCR. 
 
Discussion 
Because our previous findings had demonstrated the induction of PDGF-BB by 
HIV-1 Tat, it was critical to understand what role released PDGF-BB played in these 
cells. Based on the mitogenic function of PDGF-BB, we rationalized that PDGF-BB 
might be involved in increasing astrocyte proliferation. As expected, exogenous PDGF-
BB increased astrocyte proliferation and led to the release of the chemokine MCP-1. 
These findings are consistent with the reports on PDGF mediated induction of MCP-1 in 
fibroblast cell line and in smooth muscle cells [115, 116]. MCP-1 is a known biomarker 
of HIV neuropathogenesis [117, 118], and PDGF-mediated up-regulation of this 
chemokine can have ramifications for accelerated CNS disease in the context of HIV-1 
infection. 
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MCP-1 is a potent chemokine whose elevated levels are closely associated with 
the progression of HAND [65, 114] and whose function includes the recruitment of 
monocytes from the blood to the brain [119]. Interestingly, in addition to MCP-1, PDGF-
BB also induced IL-1β expression in astrocytes, which can have further implications in 
the amplification of toxic responses in the CNS. Exposure of astrocytes to PDGF-BB, in 
turn, led to both increased proliferation and release of pro-inflammatory cytokines MCP-
1 and IL-1β. 
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Figures 
Figure 14 
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Figure 14. PDGF-BB induces cell proliferation and proinflammatory cytokines 
expression in astrocytes. A, Representative RT-PCR gel of PDGF-βR mRNA 
expression in human A172, rat primary astrocytes, and gliomas. B, Rat gliomas and 
human A172 cell lines incubated with PDGFBB showed increased proliferation by MTT 
assay. C, mRNA isolated from human A172 cells was subjected to real-time PCR 
analysis using MCP-1 and IL-1β primers. PDGF-BB induction of MCP-1 and IL-1β 
mRNA expression in human A172 cell line. All data are presented as mean ± SD of at 
least three individual experiments. *p < 0.05, *** p < 0.001 versus control group. 
 
 
 
 
 
C 
59 
 
Chapter 5: Molecular Mechanisms of PDGF-BB-mediated MCP-1 up-regulation 
Abstract 
Chemokine (C-C motif) ligand 2, also known as MCP1 is an important factor in 
HAND.  The mechanisms, in part revolve around its neuroinflammatory processes and 
the recruitment of monocytes into the CNS via the disrupted BBB. We have previously 
demonstrated that HIV-1/HIV-1 Tat up-regulates PDGF-BB, a known cerebrovascular 
permeant and a potent inducer of MCP-1 in astrocytes.  MCP-1 alone has been shown 
to disrupt the endothelial cell barrier providing a rationale of further endothelial 
disruption by PDGF-BB. Moreover, we hypothesize that PDGF-BB-mediated disruption 
of endothelial cells is due to MCP-1. The present study was aimed at exploring the 
regulation of MCP-1 by PDGF-BB in astrocytes with implications in HAND.  Specifically, 
the data herein demonstrated that exposure of human astrocytes to human recombinant 
PDGF-BB protein significantly increased the production and release of MCP-1 at both 
the RNA and protein levels.  Furthermore, MCP-1 induction was regulated by the 
activation of ERK1/2, JNK and p38 MAP kinases and PI3K/Akt pathways and the 
downstream transcription factor, NFκB.  Chromatin Immunoprecipitation (ChIP) assays 
demonstrated increased binding of NF-κB to the human MCP-1 promoter with PDGF-
BB exposure. Conditioned media from PDGF-BB-treated astrocytes increased 
permeability of HBMECS, an effect that was blocked by STI-571, a tyrosine kinase 
inhibitor (PDGF-R blocker). PDGF-BB-mediated release of MCP-1, was the mediator of 
increased permeability in a BBB in vitro model as evidenced by the blocking antibody 
assays.  Since MCP-1 is linked to disease severity, understanding its modulation by 
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PDGF-BB could aid in understanding the proinflammatory responses in HAND. These 
results suggest that astrocyte activation exaggerates monocyte recruitment into the 
brain via MCP-1 and underscores the critical role astrocytes play in HAND. 
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Introduction 
HAND remains a common complication of HIV infection affecting up to 60% of 
infected individuals despite the use of anti-retroviral therapy (ART) [120]. With the 
advancement of ART the prevalence of HAND has actually increased partly due to 
increased survival rates of HIV infected individuals.  Among the factors involved in 
HAND pathogenesis, BBB disruption remains a critical aspect in accelerating this 
disease.  HIV infected monocyte traverse the BBB into the brain triggering a cascade of 
events including astrocyte activation resulting eventually in increased 
neuropathogenesis and neuroinflammation.  It has been well established that MCP-1, 
otherwise known as CCL2, is a major factor in the recruitment of monocytes into the 
brain that contributes to neuroinflammation and BBB disruption [44, 121]. MCP-1 is a 
chemokine that has been well studied and is expressed by a number of cell types 
including astrocytes, microglia and neurons [122, 123].  Elevated expression of MCP-1 
has been demonstrated in various diseases including multiple sclerosis, amyloid lateral 
sclerosis, lupus nephritis, peripheral neuropathy and Alzheimer’s disease [66, 124-130].  
The role of MCP-1 in contributing to disease is unclear however, enhanced MCP-1 
levels have been shown to correlate with disease progression [64, 65, 131]. 
Understanding the molecular mechanisms modulating MCP-1 may thus provide insights 
into development of therapeutic targets for many disease including HAND.  
 NF-κB, is a transcription factor known to be involved in the induction of a number 
of pro-inflammatory molecules including MCP-1 [132-134]. Under basal conditions NF-
κB exists in a bound state sequestered by an inhibitory protein, IκB.  However, following 
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stimulation by a vast number of factors, IκBα is rapidly degraded with a concomitant 
release of NF-κB p65 subunit, that is released and translocates to the nucleus, where it 
binds the promoter region to activate the transcription of specific target genes.  Due to 
the vast number of target genes that can be activated by NF-κB, it has been implicated 
in a number of cellular responses particularly immune response and inflammation.  
 PDGF is a well-known potent inducer of MCP-1.  PDGF is a family of proteins 
very closely related to the VEGF family and is highly conserved throughout the animal 
kingdom [51].  Many studies on PDGF have focused primarily on its mitogenic effects 
[49, 50, 135], however, divergent effects of PDGF are rapidly emerging.  For example, 
recent studies by Lawrence et al have demonstrated PDGF to be a cerebrovascular 
permeant that can disrupt BBB integrity during ischemia stroke conditions [94].  Along 
similar lines, it has been shown that PDGF-BB can disrupt BBB via modulation of 
molecules important in maintaining tight junctions like ZO-1 and adhesion molecules 
[136].   
Since astrocytes are a major source of MCP-1 in the brain and PDGF-BB has 
been shown to be an inducer of MCP-1, the purpose of this study was to explore the 
modulation of MCP-1 by PDGF-BB (released from Tat-treated astrocytes).  Human 
astrocyte A172 cells were treated with PDGF-BB and MCP-1 expression was 
monitored.  Utilizing pharmacological and genetic approaches, we demonstrated the 
involvement of ERK1/2, JNK and p38 MAPKs, PI3K/Akt pathways and the transcription 
factor NF-κB in PDGF-BB-mediated induction of MCP-1 in astrocytes.  Furthermore, 
MCP-1 released from astrocytes results in increased permeability of HBMECs.  These 
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data highlight the role of PDGF-BB in astrocytic dysfunction and BBB disruption via 
MCP-1 release and underscore PDGF signaling as a potential therapeutic target of 
HAND. 
Materials and Methods 
Materials 
Recombinant human PDGF-BB was purchased from R&D Systems. All 
experiments involving the treatment of cells with exogenous PDGF-BB were conducted 
under serum-free conditions because serum induces PDGF. STI-571, an inhibitor of 
tyrosine kinase receptors, was obtained from Novartis. The specific 
phosphatidinylinositol-3’ kinase (PI3K) inhibitor LY294002, MAP kinase kinase (MEK) 
inhibitor U0126 and Janus kinase (JNK) inhibitor SP600125 and p38 mitogen activated 
kinase (p38) inhibitor SB203558 were purchased from Calbiochem. MCP-1 neutralizing 
antibody was obtained from eBioscience.  The CCR2 antagonist, RS 102895 was 
purchased from Sigma. Chromatin immunoprecipitation (ChIP) assay kit was purchased 
from Upstate.  
Cell culture and cell lines 
The human astrocytic cell line A172 (ATCC #CRL-1620; American Type Culture 
Collection) were cultured as described previously and maintained in DMEM high 
glucose medium containing 10% heated-inactivated fetal bovine serum, 2 mM 
glutamine, penicillin (100 units/ml), streptomycin (100 µg/ml), essential amino acids and 
vitamins.  In this study, A172 cells were used within 30 passages. Human primary 
astrocytes were obtained from the Congenital Defects Lab (University of Washington) 
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and were cultured in DMEM medium (Invitrogen Life Technologies) containing 10% 
heat-inactivated FBS, 2 mM glutamine, sodium bicarbonate, gentamicin, nonessential 
amino acids and vitamins. Primary human brain microvascular endothelial cells 
(HBMECs) were cultured in RPMI 1640 containing 10% heat-inactivated fetal bovine 
serum, 10% Nu-Serum, 2 mM glutamine, 1 mM pyruvate, penicillin (100 U/ml), 
streptomycin (100 µg/ml), essential amino acids and vitamins.   
 
MCP-1 protein analysis by ELISA 
MCP-1 levels were examined using a MCP-1 enzyme-linked immunosorbent 
assay (ELISA) kit purchased from R&D Systems. Samples were analyzed for MCP-1 
protein according to the manufacturer’s instructions in at least triplicate determined in 
three independent experiments. 
 
Reverse transcription and Real-Time PCR 
 Total RNA was extracted using Trizol reagent according to the manufacturer’s 
protocol (Invitrogen Life Technologies).  1 µg of RNA was used for cDNA production 
according to manufacturer’s instructions (Thermo Scientific). The sequences of primers 
used for MCP-1 are as follows: sense:CAGCAGGTGTCCCAAAGAAGCTGT antisense: 
CCATTCCTTATTGGGGTCAGCACAGA.  The sequences of primers used for GAPDH 
were are follows: sense: TGCACCACCAACTGCTTAGC; antisense: 
GGCATGGACTGTGGTCATGAG. The sequences of primers used for PDGF-βR were 
are follows: sense: CAGAGCTGCCCATGAACGA; antisense: 
TTCTGCATGATCTCATAGATCTCGT.  The primers for CCR2 used in the first round 
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are as followed: sense: TCTGGAGACCTCAACCAAATG; antisense: 
GGAAATGCGTCCTTGTTCAA. The primers used in the second round are as followed: 
sense: CCCTGTATCTCCGCCTTCACT; antisense: TTCAGCTTGTGGCTTGTCTCA. 
Quantitative Analyses of mRNA were conducted using ABI 7500 Fast Real-Time PCR 
system (Applied Biosystems).  Data were normalized using Ct values for GAPDH in 
each sample.  To calculate relative amounts mRNA, the average Ct values were 
subtracted from GAPDH values for each target gene to provide changes in Ct value.  
Fold change in expression was calculated as log2 relative units. 
Western Blotting 
PDGF-BB treated astrocytes were lysed using the Mammalian Cell Lysis kit 
(Sigma) and the NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce) per 
manufacturer’s instructions.  Cell lysates were subjected to the separation by 12% SDS-
PAGE electrophoresis (30 µg protein per well) and transferred to polyvinylidene 
difluoride (PVDF) membranes. The blots were blocked with 5% nonfat dry milk in PBS.  
Western blots were then probed with antibodies recognizing phosphorylated forms of 
ERK1/2, JNK, p38 and Akt and total forms of ERK1/2, JNK, and AkT (Cell Signaling, 
1:500); NFκB-p65 and pIκB Cell Signalling, (1:1000); Histone  (1:1000) and β-actin 
antibodies (Santa Cruz, 1:5000).  Signals were detected by chemiluminescence 
(Pierce). 
Transduction with adenoviral constructs 
A172 cells were transduced with adenoviral constructs containing either wildtype 
(WT) or dominant-negative (DN) forms of Akt.  In addition, cells were also transduced 
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with recombinant adenoviral vectors expressing full-length p65/RelA or p65/RelA mutant 
(RelA 1-300) used at a multiplicity of infection (MOI) of 50 as previously described [137]. 
Transfection with plasmid constructs 
A172 cells were transfected with plasmid constructs containing either WT or DN 
forms of MEK.  
Short interfering RNA (siRNA) transfection 
Short interfering RNA (siRNA) targeting against PDGF-βR was obtained from 
Dharmacon. Human A172 cells were plated in 24-well plates at a density of 4 x 104 cells 
per well 1 d prior to transfection. Cell culture medium was replaced with 250 ml pre-
warmed OPTI-MEM I culture medium. Lipofectamine-2000 reagent (Invitrogen) was 
then combined with serum-free medium for 5 min at room temperature. The PDGF-βR 
siRNA was then added into the mixture described above to a final concentration of 5 
µM. The siRNA and the reagent mixture were incubated for 20 min at room 
temperature, after which the combined mixture was added to the cells. The cell culture 
plate was shaken gently for 5 s and incubated for 24 h at 37°C. Knockdown efficiency 
was determined by RT-PCR. 
Chromatin immunoprecipitation (ChIP) Assay 
Chromatin immunoprecipitation (ChIP) assay was performed according to the 
manufacturer’s instructions (Upstate) with slight modifications. After treatment of the 
cells, 18.5% fresh formaldehyde was added directly into the medium at a final 
concentration of 1% formaldehyde and incubated for 10 min at room temperature, 
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followed by quenching with 125 mM glycine. The cells were then scraped using 2 ml 
prechilled PBS containing 1X protease inhibitor mixture. The cell pellet was harvested 
by spinning at 800 x g at 4°C, and lysis buffer was add ed (provided in the kit) to harvest 
nuclei. DNA was then sheared by sonication. Fifty microliters of the sheared cross-
linked chromatin was then mixed with 20 ml protein A magnetic beads and 5 mg 
immunopreciptating Abs against NF-ΚB p65, acetyl histone H3 (as a positive control), 
and normal rabbit IgG (as a negative control) diluted in 450 ml dilution buffer overnight 
at 4°C. The magnetic beads binding Ab–chromatin compl ex was then washed with 0.5 
ml each of a series of cold wash buffers in the order of low salt buffer, high salt buffer, 
LiCl buffer, and Tris-EDTA buffer. The cross-linking of protein–DNA complexes were 
reversed to free DNA by incubation at 62°C for 2 h an d purified using DNA purification 
spin columns following the manufacturer’s instructions. Finally, the purified DNA was 
amplified via PCR to identify the promoter region contained NF-κB binding site 
“GGGCCTTTCC”. The sequence of the primers used to identify the MCP-1 promoter 
bound to NF-κB were as follows: sense: GCATCAGAGCATTGACCCTCA; anti-sense: 
AGGTCAGTGCTGGCGTGAGA.  
Monocyte isolation and transmigration 
Monocytes were obtained from HIV-1, HIV-2 and hepatitis B seronegative donor 
leukopacks, and separated by countercurrent centrifugal elutriation as previously 
described [138].  Monocytes were washed with PBS and fluorescently labeled with 10 
µM Cell tracker green (Molecular Probes) for 10 min at room temperature.  Labelled 
cells (2X105 cells) were added to the upper compartments of transwell inserts and 
allowed to transmigrate at 37ºC in a humid atmosphere of 5% CO2 for 24 h.  
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Transmigrated monocytes were quantified using florescent plate reader (494nm / 
517nm excitation/emission). 
Statistical Analysis 
Statistical analysis was performed using one-way analysis of variance with a post 
hoc Student’s t test. Results were judged statistically significant if p < 0.05 by analysis of 
variance.  
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Results 
PDGF-BB-mediated up-regulation of MCP-1 in astrocytes 
All experiments involving the treatment of cells with exogenous PDGF-BB protein 
were conducted under serum-free conditions because serum induces PDGF [139]. To 
investigate the role of PDGF on MCP-1 expression, A172 cells were serum starved in 
medium containing 0.1% FBS overnight followed by treatment with recombinant PDGF-
BB (20 ng/ml) for various times and mRNA levels were assessed by RT-PCR. The 
concentration of PDGF-BB used was based on previous studies [111, 140]. Following 
exposure of A172 astrocytes to PDGF-BB, there was a time-dependent up-regulation of 
MCP-1 mRNA compared with untreated cells (Fig. 15A) with a peak induction at 6 h 
post treatment (4-fold) and a subsequent down-regulation at 12 h. 
To determine whether the increased MCP-1 mRNA expression observed 
correlate with increased protein release in astrocytes, we next examined the MCP-1 
protein levels.  Cells were serum-starved as described and treated with PDGF-BB for 0-
96 h.  The supernatants were collected and MCP-1 protein levels were assessed via 
ELISA.  As shown in Fig. 15B, PDGF-BB up-regulated MCP-1 protein levels in a time-
dependent manner with a continual increase that plateaued at 48 h post-treatment. 
Cumulatively, these data clearly demonstrate that PDGF-BB treatment mediated the 
induction of MCP-1 RNA and protein in astrocytes. 
Engagement of PDGF-βR is critical for PDGF-induced MCP-1 expression in 
astrocytes 
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Because PDGF-BB mediates its effects via binding to its cognate receptor 
PDGF-βR, our next step was to examine the role of this receptor in PDGF-BB-induced 
MCP-1 release by astrocytes.  However, before proceeding with this, it was important to 
first examine whether astrocytes indeed expressed the PDGF-βR. As shown in Fig 16A, 
both human astrocyte cell line A172 as well as well as human primary astrocytes 
expressed PDGF-βR as demonstrated by RT-PCR.   
To confirm the role of PDGF-βR played in PDGF-BB-mediated MCP-1 released 
from astrocytes, human A172 astrocytes and human primary astrocytes were pretreated 
with STI-571, PDGF-βR blocker, followed by PDGF-BB treatment.  As shown in Fig. 
16B, STI-571 inhibited PDGF-BB-mediated induction of MCP-1 mRNA in both human 
A172 astrocytes as well as human primary astrocytes.  This was further confirmed by 
examining MCP-1 protein released from these astrocytes by ELISA. As shown in Fig. 
16C, pretreatment of astrocytes with STI-571 also abrogated PDGF-BB mediated 
release of MCP-1 protein as demonstrated by ELISA. Further validation of the 
involvement of PDGF-βR in PDGF-BB-mediated MCP-1 release was confirmed by 
knocking down the expression of PDGF-βR using the siRNA approach and then 
assessing the effect on PDGF-BB-mediated induction of MCP-1. As shown in Fig. 16D, 
transfection of human A172 cells with PDGF-βR siRNA resulted in efficient knockdown 
of PDGF-βR as demonstrated by RT-PCR.  Cells were transfected with either PDGF-βR 
siRNA or non-specific (Non) siRNA control followed by treatment with PDGF-BB for 24 
h.  PDGF-BB-mediated induction of MCP-1 mRNA was attenuated in the cells 
transfected with PDGF-βR siRNA but not in the Non siRNA controls cells (Fig. 16E).   
These results were further confirmed by examining PDGF-BB-mediated induction of 
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MCP-1 protein levels.  As shown in Figure 16F, PDGF-BB enhanced release of MCP-1 
protein in non siRNA transfected cells but not in cells transfected with PDGF-βR siRNA. 
Taken together, these findings confirm the involvement of PDGF-βR in PDGF-BB-
mediated induction of MCP-1 in astrocytes. 
PDGF-BB-mediated induction of MCP-1 involves MAPK and PI3K/Akt cell 
signaling pathways. 
Having determined PDGF-BB-mediated induction of MCP-1, we next sought to 
elucidate the signaling pathways involved in this process. Since PDGF-BB is a mitogen 
and a pro-survival protein, we examined the involvement of mitogen- activated protein 
kinase (MAPK) and phosphoinositide-3-kinase/ Akt pathways.  Human A172 cells were 
exposed to PDGF-BB and phosphorylation of MAPK and PI3K/Akt signaling molecules 
were assessed by western blotting.  Treatment of astrocytes with PDGF-BB resulted in 
a time-dependent increase in phosphorylation of ERK1/2, JNK, p38 and Akt, with 
maximal activation at 30 min following treatment (Fig. 17A).  To address the functional 
role of MAPK and PI3K/Akt in PDGF-mediated induction of MCP-1 expression, A172 
cells were pretreated with inhibitors specific for the respective signaling pathways 
followed by PDGF-BB treatment and subsequently assessed for expression of MCP-1. 
As shown in Fig. 17B, treatment of cells with MEK (U0126, 1 µM), JNK (SP600125, 10 
µM), P38 (SB20358, 1 µM) and PI3K (LY294002, 1 µM) inhibitors resulted in 
amelioration of PDGF-BB-mediated induction of MCP-1 protein levels. 
 Further validation of the involvement of MAPK pathway in this process was 
confirmed by transfecting cells with either the WT or DN constructs of MEK followed by 
72 
 
treatment with PDGF-BB. PDGF-BB-mediated induction of MCP-1 was attenuated by 
DN-MEK, but not by WT-MEK construct (Fig. 17C). To confirm the role of PI3K/Akt in 
PDGF-BB-mediated MCP-1, A172 cells were transduced with adenoviral constructs 
containing either WT or DN forms of Akt. As shown in Fig. 17D, cells transduced with 
DN Akt construct failed to up-regulate MCP-1 unlike the cells transduced with the WT 
Akt construct. Taken together, these findings confirm the involvement of both MAPK 
and PI3K/Akt cascades in PDGF-BB-mediated induction of MCP-1 in astrocytes. 
Involvement of PDGF-βR in the regulation of MAPKs and PI3K/Akt cell signaling 
pathways. 
Since PDGF-BB acts through its cognate receptor, the next logical step was to 
link the MAPK and PI3K/Akt pathways to PDGF-βR. To achieve this, activation of the 
MAPK and Akt pathways by PDGF-BB was validated using the PDGF-βR blocker – STI-
571.  A172 cells were pretreated with STI-571 (30 min) prior to PDGF-BB treatment for 
1h and assessed for activation of phosphorylated forms of ERK, JNK, P38 and Akt 
using western blotting.  As shown in Fig. 18A, STI-571 pretreatment attenuated 
activation of ERK, JNK, p38 and Akt induced by PDGF-BB.  These results were also 
confirmed by knocking down the expression of PDGF-βR using the siRNA approach 
and assessing the ERK, JNK, p38, JNK and Akt phosphorylation. Briefly, A172 cells 
were transfected with PDGF-βR siRNA for 24 h followed by treatment with PDGF-BB for 
1h. Cells transfected with PDGF-βR siRNA failed to demonstrate PDGF-BB-mediated 
activation of ERK, JNK, p38 and Akt (Fig.18B).  Collectively, these results underpin the 
role of PDGF-βR in PDGF-BB- mediated activation of MAPK and P13K/Akt pathways. 
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Involvement of NF-κB in PDGF-BB-induced expression of MCP-1 in astrocytes 
Having determined the role of MAPK and PI3K/Akt in PDGF-BB-mediated 
induction of MCP-1 expression, we rationalized the involvement of NF-κB in this 
process since this transcription factor is downstream of the aforementioned signaling 
mediators [132, 134, 141].  Exposure of astrocytes to PDGF-BB resulted in a time-
dependent increase of p65 subunit of NF-κB in the nucleus with a concomitant increase 
in cytosolic pIκB (Fig.19A). Validation of the role of NF-κB was further determined by 
pretreating astrocytes with the IκB pathway inhibitor (SC514), followed by PDGF-BB 
treatment.  As shown in Fig. 19B, SC514 inhibited PDGF-BB-mediated induction of 
MCP-1, thereby underscoring the role of NF-κB in this process. 
To further confirm the role of NF-κB in PDGF-B-mediated induction of MCP-1, 
A172 cells were transduced with WT or DN adenoviral constructs of NFκB. As shown in 
Fig. 19C, transduction with DN form of NF-κB resulted in inhibition of PDGF-BB-
mediated induction of MCP-1. Transduction with the WT-NF-κB construct, on the other 
hand, as expected did not inhibit PDGF-BB-mediated induction of MCP-1.  Together, 
these findings underpin the role of NF-κB in PDGF-BB-mediated induction of MCP-1 in 
astrocytes.  
To validate the role of NF-κB , we next sought to confirm the binding of NF-κB 
with MCP-1 promoter in its natural chromatin context by chromatin immunoprecipitation 
to reveal active sites accessible to NFκB.  A172 cells were treated with PDGF-BB for 1h 
followed by RNA extraction and processed using a ChIP Analysis kit.  These 
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experiments revealed increased binding of NF-κB to the MCP-1 promoter in A172 cells 
treated with PDGF-BB (Fig. 19D,E).    
MCP-1 released from astrocytes increases monocyte transmigration across 
human brain microvascular endothelial cells.  
 Having determined the induction of MCP-1 by PDGF-BB, the next step was to 
explore the functional relevance of this up-regulation.  Since MCP-1 is a known 
chemoattractant we hypothesized that PDGF-BB-induced MCP-1 released from the 
astrocytes could, in fact, act on neighboring endothelial cells altering its function.  
Endothelial cells of the BBB play a vital role in the development of HAND because it 
serves as the conduit by which infected immune cells migrate across the BBB into the 
brain in response to increased MCP-1 concentration in the brain thereby disrupting the 
BBB. Compromise of BBB in HAND has been substantiated by a number of laboratory 
animal models and human studies, demonstrating BBB breakdown as a consequence 
of progressive viral infection and immune compromise [142-144].  We thus set out to 
examine the effect of MCP-1 released from astrocytes on BBB function. However, 
before proceeding with this, it was important to first examine whether HBMECs 
(paracrine action) as well as astrocytes (autocrine action) indeed expressed the MCP-1 
receptor, CCR2. As shown in Fig. 20A, both astrocytes as well as HBMECs expressed 
CCR2 mRNA as demonstrated by RT-PCR.        
 To determine the functional relevance of increased MCP-1 induced by PDGF-BB 
in this study, A172 cells were treated with or without PDGF-BB for 2 h then replaced 
with fresh media and incubated for 24h. Endothelial cells were grown on the upper 
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compartment of transwell plates and spent media was added to the lower compartment 
overnight.  Labeled human monocytes were added to the upper compartment for 24 h 
and monocyte transmigration was assessed. As shown in Fig. 20B, conditioned-media 
collected from PDGF-BB treated astrocytes resulted in a significant increase in 
permeability. PDGF-βR blocker STI-571 was able to block the increased permeability 
mediated by conditioned media from PDGF-BB treated astrocytes.   
To investigate whether this increased in monocyte transmigration was indeed 
mediated by MCP-1, conditioned media was treated with MCP-1 neutralizing antibody 1 
h prior to treatment with the cells.  As shown in Fig. 20B, conditioned media from A172 
cells treated with PDGF-BB resulted in a dramatic increase in permeability of 
endothelial cells which was ameliorated by MCP-1 neutralizing antibody. These findings 
thus confirm that MCP-1 was involved in PDGF-BB mediated disruption of the 
endothelial barrier permeability. These results not only underpin the role of MCP-1 in 
BBB breakdown, but reveal a vital role that Tat-mediated PDGF-BB may play in BBB 
disruption.  
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Discussion 
Anti-retroviral therapies have proven highly effective in controlling systemic viral 
infection, thus leading to increased longevity in patients with AIDS.  The inability of 
some of these drugs to cross the BBB results in slow and smoldering infection in the 
CNS.  Subsequently, the brain becomes a sanctuary of virus-induced toxicity leading to 
increased prevalence of HAND in HIV-infected individuals.  One of the hallmark features 
of HAND is increased astrogliosis comprising of increased numbers of activated 
astrocytes, culminating ultimately into increased neuronal degeneration. It is well 
recognized that activation of astrocytes leads to the release of a barrage of 
inflammatory mediators as well as factors such as PDGF-BB.  PDGF-BB has been 
implicated in a variety of pathological conditions, however, its role in HIV pathogenesis 
remains poorly defined.  
In the present study we demonstrated that PDGF-BB treatment of human 
astrocyte cell line and primary cultures resulted in induction of MCP-1 and this process 
was mediated via the binding of PDGF-BB to its cognate PDGF-βR.  These findings are 
consistent with the reports on PDGF-mediated induction of MCP-1 in other cell types 
such as the fibroblast cell line and smooth muscle cells [115, 116]. In our efforts to 
dissect the upstream signaling events mediating MCP-1 release in astrocytes, we 
demonstrate the role of MAPK and PI3K/Akt in meditating MCP-1 release from 
astrocytes using both the pharmacological as well as genetic approaches. The 
involvement of MAPK and PI3K/Akt pathways in the induction of MCP-1 expression are 
in agreement with the role these pathways play in induction of this chemokine in other 
cell types including osteoblasts, mesangial cells and endothelial cells [145-147]. The 
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transcription factor, NF-κB is known to play a key role in PDGF-BB signaling and also in 
the expression of proinflammatory cytokines/chemokines including MCP-1 [132-134].  
Consistent with other reports, our studies also revealed that PDGF-BB-mediated 
induction of MCP-1 involved NF-κB activation and binding to the MCP-1 promoter.  
It was next of interest to explore the functional relevance of PDGF-BB mediated 
induction of MCP-1. Based on the proximity of astrocytes to the endothelial barrier, we 
rationalized that induced expression of MCP-1 in PDGF-BB treated astrocytes could 
play a role in barrier integrity. Intriguingly, conditioned media from PDGF-BB treated 
astrocytes did indeed increase monocyte transmigration and this effect was attributable 
to MCP-1 as demonstrated in the blocking antibody experiments. This role of MCP-1 is 
in agreement with the findings reported by Eugenin et al  who demonstrated that HIV 
infected leukocytes transmigration across a tissue culture model of human BBB was 
due to MCP-1 [117]. In addition to disrupting the barrier permeability, MCP-1 is a known 
biomarker of HIV neuropathogenesis [117, 118], owing to its role as a chemoattractant. 
The function of MCP-1 demostrated in this study can have ramification in the 
pathogenesis of HAND. Based on the proximity of astrocytes to the endothelium and 
their ability to secrete both PDGF-BB and the chemokine MCP-1 and their abundance in 
the CNS, it can be argued that during HIV-1 infection, viral proteins can initiate a toxic 
cascade that can be self-perpetuating. HIV-1 Tat can trigger increased expression of 
PDGF-BB, which in turn, can lead to increased MCP-1 expression that can manifest as 
an amplified influx of monocytes into the CNS. PDGF-BB has already been shown to 
disrupt the BBB [136] and a similar function has been demonstrated for MCP-1 [117]. 
Therefore the release of both these mediators can independently disrupt the endothelial 
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barrier while enhancing neuroinflammation [117, 136] which can have serious 
ramifications in HAND.  
In summary, our studies have mapped out a detailed molecular pathway of 
PDGF-BB-mediated MCP-1 expression in astrocytes involving ERK1/2, JNK MAPK 
activation, with the subsequent activation of NF-κB  resulting in increased MCP-1 
expression, ultimately leading to monocytes transmigration and increased permeability 
in the brains of individuals infected with HIV illustrated schematically in Figure 21. 
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and decline thereafter. B, Time-dependence of PDGF-BB-mediated induction of MCP-1 
protein expression in human A172 astrocytes. Supernatant fluid from human A172 cells 
treated with PDGF-BB for various time points were assessed for release of chemokine 
MCP-1 using the human MCP-1ELISA array.  PDGF-BB treatment resulted in induction 
of MCP-1 expression. All the data are presented as means ± of 3 individual 
experiments.  **p < 0.01, ***p < 0.001 versus control group. 
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Figure 16. Engagement of PDGF
expression in astrocytes. A, Human A172 primary astrocytes express PDGF
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RT-PCR analysis using PDGF
A172 and primary astrocytes with PDGF
mediated induction of MCP-1 mRNA and protein (
A172 cells transfected with either nonsense (Non) or PDGF
D 
F 
83 
 
 
 
-Rβ is critical for PDGF-BB induced MCP
-Rβ and GAPDH primers. B, Pretreatment of human 
-Rβ antagonist STI-571 abrogated PDGF
C) expression. D.  Total RNA from 
-Rβ siRNAs were subjected 
E 
-1 
-Rβ. RNA 
-BB-
84 
 
to RT-PCR analysis using primers for PDGF-Rβ. E, PDGF-Rβ siRNA, but not Non 
siRNA inhibited PDGF-BB-mediated induction of MCP-1 RNA. F, Supernatants from 
A172 cells transfected with either nonsense (Non) or PDGF-Rβ siRNAs were subjected 
to ELISA assay specific for MCP-1. PDGF-Rβ siRNA, but not Non siRNA inhibited 
PDGF-BB-mediated induction of MCP-1 protein.  **p ≤ 0.01, ***p ≤ 0.001 versus control 
group, #p ≤ 0.05, ###p ≤ 0.001 versus PDGF-BB-treated group. 
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Figure 17. PDGF-BB-mediated induction of MCP-1 expression involves MAPKs and 
PI3K/Akt cell signaling pathways. A, WB analysis of time-dependent activation of ERK, 
JNK, P38 and Akt by PDGF-BB. B, Inhibition of the ERK, JNK, p38 and Akt pathways 
by MEK1/2 (U0126), JNK (SP600125),  p38 (SB20358) and PI3K  (LY294002) inhibitors 
resulted in amelioration of PDGF-BB-mediated induction of MCP-1 expression in 
astrocytes. C, Transfection with DN-MEK and not WT-MEK resulted in abrogation of 
PDGF-BB-mediated induction of MCP-1. D, Transduction with DN-Akt and not WT-Akt 
also resulted in abrogation of PDGF-BB-mediated induction of MCP-1.  All the data are 
presented as means ± of 3 individual experiments. * p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 
versus control group, ##p ≤ 0.01, ###p ≤ 0.001 versus PDGF-BB-treated group. 
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Figure 18. Involvement of PDGF
signaling pathways.  A, Pretreatment of A172 cells with 
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Figure 19. PDGF-BB mediated induction of MCP
activation.  A, Exposure of A172 cells to PDGF
increase in phosphorylation of the p65 subunit of 
Reciprocally, PDGF-BB exposure resulted in a time
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Figure 20 
 
 
 
 
 
 
 
 
 
 
Figure 20. PDGF-BB-induced monocyte transmigration is mediated by MCP
isolated from untreated HBMECs and human A172 astrocytes were subjected to RT
PCR analysis using CCR2 primers. B,
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Figure 21 
 
 
 
 
 
 
 
 
Figure 21. Schematic of the signaling pathways involved in the increased induction of 
MCP-1 release in astrocytes stimulated with PDGF-BB. PDGF-BB-mediated activation 
of ERK1/2, JNK p38 MAPKs, and PI3K/Akt signaling pathways. ERK1/2, JNK p38 
MAPKs, and PI3K/Akt signaling resulted in the subsequent activation of the downstream 
transcription factor, NFκB. Activation of NF-κB in turn leads to enhanced MCP-1 release 
and increased endothelial cell permeability as shown in Figure 21. 
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Chapter 6: Conclusions 
CNS disease remains a serious complication in individuals infected with HIV-1. 
The early viral protein, HIV-1 Tat has been shown to be a critical determinant for both 
viral replication and survival. However, in the infected host release of Tat from the 
infected cells can have serious consequences, as it exerts potent toxicity on various cell 
types in the brain. In the CNS it can activate monocytes, astrocytes and microglia, 
which, in turn, leads to a “cytokine/chemokine storm” in the CNS. HIV-1 Tat not only 
exerts direct toxicity on the neurons, but can also indirectly lead to neuronal apoptosis, 
via the mediators released from other neighboring cells. These complex cascades of 
events could be self-propelling, thereby perpetuating a continuum of inflammatory 
responses in the brain of HIV-1 infected individuals. These are important issues even in 
the current era of anti-retrovirals, since most of the therapeutic drugs do not cross the 
BBB. HIV Tat can also disrupt the BBB integrity, allowing for increased numbers of 
inflammatory cells into the CNS. Furthermore, Tat can also co-operate with various 
drugs of abuse to potentiate toxicity thereby amplifying untoward inflammatory 
responses in the CNS. HIV-1 Tat thus acts at multiple steps within the CNS to 
exacerbate disease pathogenesis and understanding its contributions at various stages 
of the disease process is crucial for developing strategies that could interfere with 
disease induction and/or progression. Our findings have demonstrated that in addition 
to the numerous ways in which HIV-1 Tat causes the release of toxic mediators, it can 
also utilizes PDGF-BB a well-meant protective response of the astrocyte to drive cellular 
activation via PDGF-BB-mediated increased expression of MCP-1 as illustrated in figure 
21.  MCP-1 has been shown to be both neuroprotective, however, due to its strong 
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chemoattractant property, is detrimental to the CNS as it plays a key role in recruiting 
infected monocytes into the brain.  Even in circumstances where peripheral viral loads 
are minimal, the enhanced recruitment of monocytes into the brain poses a problem as 
it disrupts the BBB allowing easier access of toxic products into the CNS. 
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Figure 22 
 
 
 
 
 
 
 
 
 
 
Figure 22. Schematic of the Tat-mediated effects astrocyte-endothelial interations via 
PDGF-BB and MCP-1. Tat-mediated activation of ERK1/2 and JNK MAPKs but not and 
PI3K/Akt and p38 signaling resulted in the activation of the downstream transcription 
factor, Egr-1. Activation of Egr-1 in turn leads to enhanced PDGF-BB expression in 
astrocytes.  PDGF-BB released from astrocytes can act in an autocrine manner to 
further activate astrocytes. PDGF-BB-mediated activation of ERK1/2, JNK, p38 MAPKs, 
and PI3K/Akt signaling resulted in the subsequent activation of the downstream 
transcription factor, NFκB. Activation of NF-κB in turn leads to enhanced MCP-1 release 
and disruption of endothelial cells as shown in Figure 22. 
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Chapter 7: Future Directions 
Due to the mounting evidence of glial activation on HIV neuropathogensis, it is 
critical to understand the cellular events culminating in neuronal dysfunction/toxicity.  
GIial activation remains a critical player in the production of toxic mediators released 
leading not only to neuronal dysfunction and enhanced glial activation.  The increased 
activation subsequently releases more proinflammatory cytokines/chemokines and 
other toxic mediators providing an amplification loop of exaggerated and maintained 
glial activation.  Our findings have just scratched the surface of how glial activation can 
actually aid viral CNS infection and have revealed many other potential questions that 
should be addressed in order to better understand the role of glial activation in HIV 
neuropathogesis.  Albeit, a critical factor in HIV pathogenesis, MCP-1 is one of a 
number of cytokines that can be released from activated astrocytes.  Other cytokines 
including CXCL10, IL-6 and IL-1β have also been shown to be enhanced with glial 
activation [33, 47, 48, 148-151]. Future directions may address the role of these pro-
inflammatory cytokines on the CNS. 
Because of the close proximity of astrocytes to the endothelial cells of the BBB, it 
is critical to shed some light on the detrimental effects that astrocytic modulation plays 
on BBB integrity and the recruitment of monocytes into the brain.  How astrocytes affect 
the normal functioning of cells that make up the neurovascular unit, the migration 
endothelial cells and the expression of tight junction proteins are paramount to 
designing methods of curtailing the invasion of monocytes into the brain observe in HIV 
CNS infection.  
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